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INTRODUCTION 
Gastroesophageal reflux disease (GERD) is a common disease of the 
gastrointestinal tract(1). GERD is defined as symptoms or mucosal damage as a 
result of abnormal reflux of gastric contents into the esophagus or beyond(2). 
GER (Gatroesophageal reflux) is a normal physiologic process in which there 
will be retrograde movement of gastric contents from the stomach to the 
esophagus. GER is not a disease. It occurs several times a day without mucosal 
damage or symptoms. GERD is caused by failure of anti reflux barrier. GERD 
occurs when stomach contents move to the esophagus effortlessly which cause 
the reflux symptoms like heartburn and regurgitation(3). It is a multifactorial 
process. GERD affects the quality of life. Using endoscopy, GERD can be 
classified into non erosive reflux disease and erosive esophagitis. According to 
Los Angeles classification erosive esophagitis is graded from A-D. It have a 
wide variety of clinical presentations ranging from gastrointestinal (common) to 
extra-gastrointestinal (uncommon) symptoms. Common gastrointestinal 
symptoms are heartburn, regurgitation and retrosternal chest pain. Extra-
gastrointestinal symptoms are bronchial asthma, laryngitis, hoarseness of voice, 
chronic cough, sore throat and dental erosions. Diverse studies on various 
population and lifestyle background had been reported in previous literature, 
however the data were few from our part of the country. Henceforth, warranting 
more studies representing the facts from our province of the country. 
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Furthermore, longstanding and untreated GERD leads to morbid complications 
such as esophageal ulcer, Barrett’s esophagus and esophageal stricture. 
However, variable inference had been postulated regarding the association of 
clinical, lifestyle and endoscopic characteristics associated with complications 
of GERD necessitating further exploration on this background. 
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AIM AND OBJECTIVES 
AIM OF THE STUDY: 
 To analyze the symptom profile of GERD  
 
OBJECTIVES OF THE STUDY: 
PRIMARY OBJECTIVE: 
 To evaluate the symptomatology of GERD  
SECDONDARY OBJECTIVE: 
 To analyze the dietary and lifestyle factors associated with GERD  
 To assess the prevalence of complications of GERD 
 To assess the association of clinical, lifestyle and endoscopic 
characteristics with complications of GERD 
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MATERIALS AND METHODS 
 
STUDY DESIGN      :  Cross sectional observational study 
STUDY PERIOD      :  February 2016 to July 2017 
STUDY PLACE           :  Department of Medicine, PSG Institute of  
Medical Sciences and Research, Peelamedu, 
Coimbatore 
SOURCE OF DATA    :  The present study comprised of patients who  
Were diagnosed of Gastro-esophageal reflux 
disease (GERD) based on upper gastrointestinal 
endoscopy (UGI scopy) 
SAMPLE SIZE     :  Total of 100 patients with upper gastrointestinal 
endoscopy proven Gastro-esophageal reflux 
disease 
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STUDY DESIGN 
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SELECTION CRITERIA 
INCLUSION CRITERIA: 
 Age >18 years 
 Gastro-esophageal reflux disease patients proven based on UGI scopy 
 
EXCLUSION CRITERIA: 
 Age <18 years 
 Presence of mass lesion in esophagus or stomach 
 Presence of esophageal varices 
 History of corrosive ingestion 
 Pregnant women 
 Terminally ill patients 
 Mentally challenged 
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ETHICAL CLEARANCE: 
Prior to the commencement of the study, ethical clearance was obtained from 
Institutional Human Ethical Committee, PSG Institute of Medical Sciences and 
Research, Peelamedu, Coimbatore. 
 
INFORMED CONSENT: 
The selected patients were briefed about the nature of the study and written 
informed consent was obtained from them in regional language. 
 
DATA COLLECTION: 
Patients who had been diagnosed as Gastro-esophageal reflux disease (GERD), 
based on upper gastrointestinal endoscopy were included in this study. UGI 
scopy had been considered the gold standard diagnostic test for the diagnosis of 
Gastro-esophageal reflux disease. Total of 100 UGI scopy proven GERD 
patients were included in this study. Patients were briefly explained about the 
study and informed consent was obtained from them. Subsequently, patients 
were interviewed for demographic details, lifestyle information, and 
symptomatology data. The obtained patient particulars and endoscopic findings 
were recorded in the predesigned proforma.   
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STATISTICAL ANALYSIS: 
The data obtained was coded and entered in Microsoft Excel Spreadsheet. Data 
was analyzed using SPSS version 20.0 statistical software. Descriptive statistics 
of the collected data was analyzed. Categorical variables were expressed as 
percentages and the comparative analysis was done using chi-square test or 
Fischer exact test. Continuous variables were expressed as mean ± standard 
deviation (SD) and the comparative analysis was done by independent sample‘t’ 
test. A probability value (p value) of less than or equal to 0.05 at 95% 
confidence interval was considered as statistically significant. 
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REVIEW OF LITERATURE 
ANATOMY OF THE ESOPHAGUS 
The esophagus is a long hollow muscular tube, which acts as a channel for  
movement of food from the pharynx to the stomach. The esophagus length 
ranges from 18-25 cm. The esophagus starts as the continuation of the pharynx 
at the level of C6 vertebra lower border. The esophagus is situated in between 
the trachea and the vertebral bodies. It descends in the middle mediastinum 
anterior to the vertebral column and joins cardia of stomach along the lesser 
curvature. At the level of T10 vertebra esophagus  traverses the diaphragmatic 
hiatus to enter the abdomen(4). Anatomically the esophagus is dived into three 
parts : Cervical, Thoracic and Abdominal parts. Functionally the esophagus is 
divided into upper esophageal, lower esophageal sphincter and the esophageal 
body. 
 
EMBRYOLOGY OF THE ESOPHAGUS 
The period from the fertilization up to the eight week is called the embryonic 
period. The period from the ninth week till birth is called the fetal period (4). 
The endoderm and the mesoderm are the two germ layers that forms the 
digestive tube. The endoderm is in the form of flat sheet at the beginning, later 
the sheet is converted into a tube (called the gut)  by the  formation of head, 
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lateral folds of the embryonic disc and the tail.  The gut is divided into the 
forgut, midgut and the hindgut(5). The esophagus is derived from the foregut. 
The other foregut derivatives are the  stomach, the duodenum, the pancreas, the 
liver, the biliary apparatus, the pharynx,  derivatives of the pharyngeal pouch, 
parts of the floor of the mouth (including the tongue), the thyroid and the lower 
respiratory tract. The trachea and the esophagus is separated by a septum called 
the tracheoesophageal septum.  The esophagus is short at first, but rapidly 
elongates. The  esophagus elongates with the formation of the neck (ascent of 
the pharynx), pleural cavity enlargement and with the decent of the diaphragm. 
Around the seventh week the esophagus reaches its final  relative length. The 
esophageal musculature is derived from the mesenchyme. The mesenchyme 
forms striated muscle in the upper two-thirds of the esophagus and in the lower 
one-third of the esophagus, the smooth muscles(5). The lumen of the esophagus 
is totally occluded due to the epithelial proliferation, re-canalization takes place 
at the end of the embryonic period (after the eight week). 
 
SPHINCTERS OF THE ESOPHAGUS 
 The esophagus has two sphincters, the upper esophageal sphincter(UES) and 
the lower esophageal sphincter(LES).  
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UPPER ESOPHAGEAL SPHINCTER 
The upper esophageal sphincter is located at the lower end of the pharynx, 
sometimes also referred to as inferior pharyngeal sphincter(6). The upper 
esophageal sphincter is an anatomical sphincter, consists of striated muscle. The 
upper esophageal sphincter is located behind the cricoid cartilage. It is a high-
pressure zone. It is made up of the  cricopharyngeus(CP)  muscle, 
thyropharyngeus(TP) muscle and the cervical esophagus(7). The tone of upper 
esophageal sphincter is maintained by all the three muscles. In all physiological 
states only the cricopharyngeus muscle can contract and relax. During the 
process of swallowing the upper esophageal sphincter opens to allow the 
passage of food into the esophagus. The upper esophageal sphincter has two 
important functions, first it prevents the entry of air during breathing into the 
food pipe and second function is that it protects from airway aspiration by 
preventing the entry of esophageal contents into the pharynx(6).   
 
LOWER ESOPHAGEAL SPHINCTER 
The lower esophageal sphincter is located in the lower end of the esophagus at 
the  gastro-esophageal junction (junction between the esophagus and the 
stomach). The gastro-esophageal junction is located at the level of T11 vertebra 
to the left. At this junction the esophageal mucosa is changed to gastric mucosa.  
The lower esophageal sphincter is a physiological / functional sphincter. It is a 
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high pressure zone. In autopsy specimens there is no muscle thickness at the 
gastro-esophageal junction. In live humans intraluminal ultrasound imaging 
shows thick muscle layer (both circular and longitudinal muscles) at the LES 
region. The thickness of muscle increases and decreases with the LES pressure 
change. This explains that the absence of muscle tone in autopsy specimen is 
responsible for the lack of muscle mass(8). The sphincter is formed by  four 
phenomena: a)The esophagus enters at an acute angle into the stomach, b)The 
positive intra-abdominal pressure helps in compression of the walls of 
esophagus in the intra-abdominal section, c) The folds of mucosa at the gastro-
esophageal junction helps in narrowing of the lumen, d) The right crus of the 
diaphragm acts as a clamp. The lower esophageal sphincter relaxes during 
swallowing (peristalsis) to allow the passage of food from the esophagus into 
the stomach(9). The lower esophageal sphincter at rest, contracts to prevent the 
reflux particles (stomach acids and the chyme) entry into the esophagus. 
 
HISTOLOGY OF THE ESOPHAGUS 
The esophageal wall is composed of four layers: 
a)Mucosa: Non- keratinized stratified squamous epithelium, changes to 
columnar epithelium at the gastro-esophageal junction 
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b)Sub mucosa: Contains loose connective tissue with esophageal glands, 
vessels, lymphatics, nerves and Meissner's plexus 
c)Muscularis propria: consists of outer longitudinal fibers and inner circular 
fibers. The lower one-third of the esophagus is made up of smooth muscle 
fibers, the middle one-third of the esophagus contains mixed fibers (both 
skeletal and smooth fibers), the upper one-third of the esophagus is made up of 
skeletal fibers. 
d)Adventitia: Consists of loose areolar connective tissue. Devoid of serosal 
layer hence infections and tumors can disseminate rapidly (10). 
 
ANATOMY OF THE STOMACH 
The stomach is J shaped muscular sac. The stomach is a widest part of the 
digestive tract. It is lies in between the esophagus and the small intestine. It is 
covered by peritoneum. The stomach is situated at level of  T10 and L3 
vertebra. The stomach lies in the epigastric, umbilical and left hypochondriac 
regions, and most of the stomach is covered by the ribs. The stomach is 
anatomically divided into four regions(11): 
a) The cardia: The area just distal to the gastro-esophageal junction 
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b) The fundus of the stomach: The area above and to the left of the gastro-
esophageal junction. 
c) The body of the stomach: The area in between the fundus and the antrum, it 
is the largest area of the stomach. 
d) The pyloric part: It is the distal end of the stomach, sub-divided into the 
pyloric antrum and the pyloric canal.   
The stomach has two openings- Gastro-esophageal and the pyloric opening. It 
has two sphincters - The cardiac sphincter closes the top end of the stomach and 
the pyloric sphincter which closes the bottom.   
 
EMBRYOLOGY OF THE STOMACH 
The stomach is derived from the foregut. The stomach initially appears just 
distal to the esophagus, as a fusiform dilation of the foregut. It is attached to the 
posterior abdominal wall by dorsal mesogatrium. The stomach is attached to the 
septum transversum by ventral mesogastrium. Dorsal and ventral mesogastrium 
are  folds of peritoneum. 
 The septum transversum forms the liver and the diaphragm. The lesser 
omentum is formed by the parts of ventral mesogastrium between the stomach 
and the liver. The parts of ventral mesogastrium between the liver and the 
diaphragm forms the falciform and the coronary ligaments.  
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The development of the spleen separates the dorsal mesogastrium into two 
parts, the gastrosplenic ligament and the lienorenal ligament. The gastrospenic 
ligament is made by the part of dorsal mesogastrium between the spleen and the 
stomach. The lienorenal ligament is made by the part of dorsal mesogastrium 
between the posterior abdominal wall and the spleen. As the stomach grows, 
there is notable change in its orientation and  shape. The ventral border becomes 
the lesser curvature, facing upwards and to the left. The dorsal border becomes 
the greater curvature, pointing downwards and to the left. The right surface 
becomes the posterior surface and the left surface becomes the anterior 
surface(12). 
 
HISTOLOGY OF THE STOMACH 
The mucosa is made up of simple columnar epithelium and gastric pits(13). 
Based on the nature of the glands stomach is divided into three histological 
areas: Cardiac, Fundic and the Pyloric region. 
 Cardiac Region of Stomach 
Mucosa: consists of simple columnar epithelium with oval nuclei. Lamina 
propria contains the mucus secreting cardiac glands. 
Sub mucosa: consists of connective tissue. 
Muscle layer: outer longitudinal and inner circular muscle layer. 
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Serosa: consists of simple squamous epithelium. 
Fundic Region of Stomach 
Mucosa: consists of simple columnar epithelium with oval nuclei. Lamina 
propria contains the gastric glands. The cells of fundic region are: Chief cells, 
Parietal (oxyntic) cells, mucus neck cells, enteroendocrine cells and the 
undifferentiated cells. 
Sub mucosa: consists of Meissner's plexus, blood vessels and lymphatics. 
Muscularis externa: outer longitudinal layer, middle circular muscle layer and 
an inner oblique layer. 
Serosa: consists of flattened surface layer of mesothelial cells on thin connective 
tissue layers along with lymphatics and blood vessels.  
Pyloric Region of Stomach 
Mucosa: Lmina propria contains the pyloric glands. The gastric pits are deep, 
reach half the mucosal thickness. 
Muscularis externa: outer longitudinal layer and an inner circular layer. 
Sub mucosa and Serosal layers are same as the fundic region.  
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GASTROESOPHAGEAL REFLUX DISEASE (GERD) 
Gastroesophageal reflux disease (GERD) is a common disease of the 
gastrointestinal tract(1). GERD is defined as symptoms or mucosal damage as a 
result of abnormal reflux of gastric contents into the esophagus or beyond(2). 
GER (Gatroesophageal reflux) is a normal physiologic process in which there 
will be retrograde movement of gastric contents from the stomach to the 
esophagus. GER is not a disease. It occurs several times a day without mucosal 
damage or symptoms. GERD is caused by failure of anti reflux barrier. GERD 
occurs when stomach contents move to the esophagus effortlessly which cause 
the reflux symptoms like heartburn and regurgitation(3). It is a multifactorial 
process. GERD affects the quality of life. Using endoscopy, GERD can be 
classified into non erosive reflux disease and erosive esophagitis. According to 
Los Angeles classification erosive esophagitis is graded from A-D.  
Complications of GERD include upper gastrointestinal haemorrhage, 
eosophageal stricture, barrett's esophagus, dysplasias and esophageal 
malignancy. 
 
EPIDEMIOLOGY 
In the last 2 decades the prevalence of GERD has increased(14). The exact 
prevalence rate of GERD is difficult to find out, because many affected 
individuals are asymptomatic. The prevalence may be underestimated with data 
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based on esophagitis (mucosal damage). Esophageal pH monitoring on large 
scale is not possible. In United States, Gallup Organization conducted a 
population survey and found out that 44% of the participants had heartburn once 
a month(15).  From another study in Olmsted Country, Minnesota, the 
prevalence was 42% for heartburn and 45% for acid regurgitation. 20% of 
participants had weekly symptoms(11). GERD prevalence is higher in the 
western countries and it is increasing in India nonetheless there have been only 
few studies on GERD in India(11)(16). GERD had the highest annual direct 
costs in the United States ($9.3 billion)(17). GERD prevalence estimates was 
18.1%-27.8% in North America, 8.8%-25.9% in Europe, 2.5%-7.8% in East 
Asia, 8.7%-33.1% in the Middle East, 11.6% in Australia and 23.0% in South 
America(18). In one study 7.6% of Indian subjects had significant GERD 
symptoms(19). In another study the prevalence of GERD was 22.2 % in 
southern India(20). Male and female are equally affected by GERD, whereas 
esophagitis and barrett's esophagus are predominant in male gender. The 
prevalence of complications of GERD are associated with increasing age, 
probable reason being as a result of accumulative injury by the acid to the 
esophagus over the years(21). From one study the prevalence of GERD has 
increased along with the increase in obesity(22). In contrary, a study among 
older adult men from Sweden did not find an association between GERD and 
obesity(23). Another large study showed that there is significant between the 
GERD symptoms and abdominal diameter, irrespective of the BMI(24). More 
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than BMI, central adiposity may be important in GERD pathogenesis. In long 
standing GERD patients, obesity seems to be associated with complication. The 
association between obesity and GERD can be  explained by several 
mechanisms, like decreased lower esophageal sphincter pressure, increased 
intra-abdominal pressure, increase in hiatal hernia and esophageal motor 
disorders. Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) 
produced by the metabolically active visceral fat affects the lower esophageal 
sphincter function. Genetic factors may also be related with GERD prevalence. 
The mechanisms is not known.  
 
PATHOGENESIS 
 GERD has a complex pathogenesis, it is the result of imbalance between the 
defensive factors protecting the esophagus and aggressive factors refluxing from 
the stomach. The protective factors include antireflux barriers, tissue resistance 
and esophageal acid clearance. The aggressive factors are gastric acidity, 
volume and duodenal contents. 
Multiple factors involved in the pathogenesis of GERD (25):  anatomical 
abnormalities (like hiatus hernia), transient LES relaxations (tLESRs),  
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impaired tone of  lower esophageal sphincter (LES), impaired clearance of acid 
in the esophagus and prolonged gastric emptying, mucosal resistance is 
impaired. 
 
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS 
In healthy individuals, tLESRs is responsible for all reflux episodes and in 
GERD patients it responsible for 50% to 80% of reflux episodes(26). tLESRs is 
the most common mechanism causing reflux in patient who have normal 
sphincter pressures. tLESRs are not dependent on swallowing. They persist 
longer. From one study among patients with nonreducible hiatal hernias, it was 
found  that the primary mechanism of GER was low basal LES pressure, and 
not tLESRs(27). tLESRs does not produce GER always. GER due to tLESRs 
occurs in 40% to 60% of  normal subjects, and 60% to 70% in patent with 
GERD(28).  Factors responsible for reflux are duration of tLESRs, hiatal hernia, 
abdominal straining and esophageal shortening degree. The main stimulant 
responsible for tLESRs is proximal stomach distension  by food or gas, because 
of tLESRs belching occurs. Drugs impairing  tLESRs are anticholinergic drugs, 
somatostatin, cholecystokinin A (CCK-1) receptor antagonists, nitric oxide 
inhibitors, morphine, γ-aminobutyric acid (GABAb) agonists, and 5-
hydroxytryptamine (5-HT) antagonists. Evidence suggest that vagal pathways 
are responsible for the tLESRs.  
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SWALLOW-INDUCED LES RELAXATION 
During swallow-induced LESRs, 5% to 10% reflux episodes occurs. Defective 
peristalsis can cause reflux(28).  Normally  swallow-induced LESR does not 
cause reflux. Reflux is common with the presence of hiatal hernia, reason being 
weak esophagogastric junction which allows reflux of acid at very low 
pressures.(29,30) 
 
HYPOTENSIVE LOWER ESOPHAGEAL SPHINCTER PRESSURE 
Hypotensive LES can cause GER by two ways, strain-induced or by free 
reflux(31,26). Strain-induced reflux occurs when intra-abdominal pressure 
increases (coughing, bending over, or straining). Free reflux occurs when 
intraesophageal pH fall with no difference in intra-gastric pressure.  Commonly 
seen in severe esophagitis patients, and it is responsible for 25% of reflux 
symptoms(26,32,33).  
 
HIATAL HERNIA 
Among reflux esophagitis patients, 54% to 94% have hiatal hernia(34). Studies 
showed the association of  hiatal hernia with severe esophagitis, and 
complications like strictures and Barrett's esophagus. Studies showed that there 
is an increased risk of erosive esophageal injury with the presence of hiatal 
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hernia in patients with reflux(35). The function of  LES is impaired by  hiatal 
hernia through several mechanism and the hiatus hernia also affects the 
esophageal acid clearance. "Non reducible" hiatal hernia patients experience 
severe reflux.  
Other causes for reflux are impaired esophageal acid clearance, esophageal 
epithelial resistance and delayed gastric emptying.  
 
CLINICAL FEATURES 
TYPICAL REFLUX SYMPTOMS 
HEARTBURN 
The symptoms like heartburn and acid regurgitation are considered to be 
reasonably specific for diagnosis of GERD(36). Heartburn is described as a 
burning feeling, arising from the lower chest or stomach and radiating up to the 
neck, throat and sometimes the back(37). Heartburn predominantly occurs 
postprandially. Heartburn also occurs after large meals, spicy foods, alcohol, 
citrus fruits, chocolates and fats. Heartburn can be aggravated by bending over 
or in supine position(38). One study demonstrated that acute auditory stress in 
GERD patients can increase the heartburn symptoms(39). Another study 
showed that GERD patients with sleep deprivation is hyperalgesic and provides 
a potential mechanism for increased severity in GERD symptoms (40). In 
another study, about one third of GERD patients are psychologically 
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distressed(41). Heartburn occurring in the night can cause sleep deprivation and 
can impair the next day work(41).  
When a patient has heartburn as a predominant symptom, then the specificity is 
high (89%) with a low sensitivity (38%) for the diagnosis of GERD compared 
with 24 hour esophageal pH monitoring(36).  
The diagnosis of GERD with symptoms is by the presence of heartburn for 2 or 
more days in a week, however less frequent symptoms does not exclude the 
diagnosis of disease(41,42). The degree of esophageal injury cannot be 
predicted by the severity and frequency of heartburn. 
Heartburn symptoms can appear from acid reflux, mechanical stimualtion of the 
esophagus, bile reflux and weakly acid reflux. Heartburn sensation is mediated 
by a receptor during acid perfusion, the receptor has not been identified. 
Capsaicin or vanilloid receptor 1 (TRPV1) is thought to be associated with 
heartburn.  TRPV1 has sensory neurons, which on activation can produce 
burning pain(36,42,43). TRPV1 is activated by acidic pH, heat and ethanol. 
Weakly acidic reflux can produce symptoms when the volume of reflux is large 
and when there is prolongation of acid-clearance(44). The bile- acid-induced 
reflux symptoms are thought to damage the lipid membranes thereby releasing 
intracellular mediators(45). The exact mechanism of bile-acid-induced 
heartburn is not known. Pepsin can damage the esophageal mucosa directly 
thereby causing increased esophageal mucosal permeability and intercellular 
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spaces dilation(46). Distention of the esophagus and sustained contractions of 
the esophagus can produce heartburn symptoms.  
 
OTHER TYPICAL SYMPTOMS 
Acid regurgitation and dysphagia are the other common symptoms of 
Gastroesophageal reflux disease. The regurgitation of acidic fluid effortlessly, 
particularly after heavy meals and it is  aggravated by supine or stooping 
position, is highly suggestive of Gastroesophageal reflux disease(36). In 
patients who have daily regurgitation, the pressure of LES is usually low, 
presence of  a  large hiatal hernia and many have  gastroparesis this makes 
regurgitation more difficult to treat than heartburn.  
Dysphagia is experienced by more than 30% of patients with Gastroesophageal 
reflux disease(46). This occurs in patients with heartburn who have long-
standing symptoms. Dysphagia slowly progresses for solid foods. The common 
etiologies for dysphagia are stricture, Schatzki's ring, and other causes are 
esophageal  cancers, severe esophageal inflammation and peristaltic 
dysfunction.  
Less common symptoms of Gastroesophageal reflux disease are burping, water 
brash, nausea, odynophagia, hiccups and vomiting(47). Water brash is 
experienced as a sudden appearance of salty or sour fluid in the mouth. It is 
Page | 26  
 
secreted in response to the acid from the salivary glands, and not regurgitated 
fluid.    
Most of the elderly patient with Gastroesophageal reflux disease are 
asymptomatic. The reason being less acidity in the reflux material and 
decreased perception of pain in some patients(48). Many elderly patients present 
with the GERD complications first, the reason being minimal symptoms or no 
symptoms, with long-standing disease. In patients with Barrett's esophagus, at 
the time of presentation one third of them were insensitive to acid(49).  
Patients with severe ulcerative esophagitis experience odynophagia. Other 
causes of esophagitis like impacted pill causing injury and infections must be 
ruled out(50). 
 
EXTRAESOPHAGEAL MANIFESTATIONS 
Gastroesophageal refux disease can cause a broad spectrum of symptoms 
including noncardiac chest pain, chronic cough, asthma, recurrent pneumonitis, 
posterior laryngitis  and rarely dental erosions(51). Some patients have typical 
reflux symptoms, but most of them are "silent refuxers", which make the 
diagnosis difficult. Even if  GERD can be confirmed by pH studies in patients 
with atypical symptoms, it is difficult to make a  relationship,  because patients 
may have two common diseases.  
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CHEST PAIN 
Gastroesophageal reflux (GER)-related chest pain can present with a squeezing 
or burning character, mimicking angina. Pain is mainly in the retro-sternal area 
which  radiates to the arm, back, jaws or neck. Pain is severe enough to awaken 
a patient from sleep, may be aggravated after meals, heavy exercise  and during 
emotional stress. Heavy exercise. The duration of  chest pain due to GER 
usually lasts from minutes to even  hours. Most often the chest pain resolves 
spontaneously, pain can be reduced with antacids. Most of the patients have 
heart burn symptoms associated with chest pain.  
Many studies have found that GER is the commonest esophageal cause of 
noncardiac chest pain. The mechanism is not clear for GERD-related chest pain 
and is assumed that multiple factors are involved, related to volume of acid 
reflux, concentration of H+ ion, and duration of acid reflux, prolonged 
contractions of the longitudinal muscles and the  esophageal spasm(52). Chest 
pain due to acid reflux as noted by pH testing, have good response to 
therapy(53). 
 
PULMONARY MANIFESTATIONS AND ASTHMA 
In asthma patients, the prevalence of GERD is approximately between 34% and 
89%(54). Asthmatics with symptomatic GERD, is associated with greater 
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severity of asthma. Asthmatics not responding to glucocorticoids or 
bronchodilators, presenting in adulthood,  and those  who don't have an allergic 
component, in these asthmatics  GERD should be considered(55).  Around 30% 
of  GERD-related asthmatics don't  have any esophageal symptoms . GERD is 
associated with some other respiratory diseases like, interstitial pulmonary 
fibrosis, aspiration pneumonia, bronchiectasis and chronic bronchitis. From 
preliminary data, in a subset of patients the course of obstructive sleep 
apnea(OSA) may be worsened by GER(56). Around 30% of GERD-related 
asthma  patients do not have any esophageal complaint. 
 
DISEASES OF THE EAR, NOSE, AND THROAT  
GERD patients present with hoarseness, frequent throat clearing, globus 
sensation,  sore throat, and prolonged voice warm-up, all these symptoms are 
due to laryngeal inflammation(57). Signs attributed to GERD include posterior 
laryngitis with redness and edema, ulcers in the vocal cord, leukoplakia, 
granulomas, and sometimes even carcinoma(58). These changes are most of the 
time restricted to the posterior one third of vocal cords and the inter-arytenoid 
areas, which are located near the upper esophageal sphincter. Animal studies 
showed that the combination of acid, bile acids, and pepsin are harmful to the 
larynx (59). Human studies report that increased exposure of acid to esophagus, 
is common  in patients having laryngeal symptoms(57).  
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GERD is thought to be the third commonest cause of chronic cough. Asthma 
and  sinus problem are the first two causes of cough(60). 
   
DISORDERS OF SLEEP  
Nocturnal symptoms of GERD can cause disturbed sleep, resulting in decreased 
quality of life and high rates of absenteeism from work(61). PPI therapy 
compared with placebo showed superiority in relieving nocturnal heartburn 
symptoms and also reduced sleep disturbances, thereby improving productivity 
of work and the quality of sleep(62). Studies found an association between 
obstructive sleep apnea (OSA) and  nocturnal GERD(63). In one of the study, 
this association was confirmed by using pH-impedance testing , results showed 
that OSA patients are found to have increased number  pathologic acid reflux 
episodes than those patients without OSA(64). The mechanism for the 
association between OSA and nocturnal GERD is not clear. 
  
DISEASES ASSOCIATED WITH GERD  
Many conditions can predispose to GERD. The commonest being pregnancy, 
30% to 80% of them have heartburn, predominantly in the first trimester of 
pregnancy.  In  pregnancy the LES pressure is reduced which increases the risk 
for reflux. LES pressure is decreased by the effects of progesterone and 
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estrogen(65). Mechanical factors caused by the gravid uterus can also decrease 
the LES pressure. Even with severe reflux symptoms, esophagitis is rare. This is 
type of GERD is situational which is cured after  childbirth.  
GERD is reported in up to 90% of patients with scleroderma. The reason is that 
they have low LES pressure, due to smooth muscle fibrosis and weak or absent 
peristalsis. Around 70% of patients have esophagitis. Many patients have 
reported with complications of GERD like strictures,  Barrett's esophagus and 
esophageal malignancy(66).  
In patient with Zollinger-Ellison syndrome, increased acid secretion and gastric 
volume are the main factors responsible for GERD. Esophagitis and 
complications of GERD are difficult to treat(67).  Post Heller myotomy 
procedure for achalasia, GERD is reported in 10% to 20% of patients(68). In 
obese patients who undergo laparoscopic gastric banding, GERD symptoms are 
reported  postoperatively(69). Long duration of nasogastric tube intubation can 
result in reflux esophagitis, because LES barrier function is mechanically 
interfered by the tube.  
 
DIFFERENTIAL DIAGNOSIS  
Symptoms of GERD can be imitated by other esophageal diseases and 
extraesophageal diseases like angina pectoris, peptic ulcer disease, 
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gastroparesis, achalasia, gallstones, functional dyspepsia, and Zenker's 
diverticulum. Patients on PPI therapy with no improvement in symptoms and 
specific diagnostic tests can identify these disorders. The commonest cause of 
esophagitis is GERD, other etiologies of esophagitis like infections, pills, or 
radiation should be thought in difficult-to-manage cases, elderly people, or 
immuno-compromised patients. 
  
DIAGNOSIS  
There are many tests available for diagnosis of GERD. In many situations, the 
typical symptoms like the heartburn and the acid regurgitation are specific 
enough for diagnosis of GERD and initiation of treatment.  
 
EMPIRICAL TRIAL OF ACID SUPPRESSION 
With the development of Proton pump inhibitor (PPIs), the empirical trial of 
acid suppression has become the first test and cost effective test in the diagnosis 
of GERD(70). It is the definitive and simplest method for the GERD diagnosis. 
PPIs are tried in patients with typical symptoms for one or two weeks. If 
patients become asymptomatic with PPIs and again experience symptoms when 
PPIs are discontinued, then the diagnosis of GERD is made. In some heartburn 
trials empirical therapy is with high dose of PPI for at least two weeks (e.g., 
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omeprazole 40 to 80mg / day), if the heartburn is reduced by 50% with therapy 
then it is called a positive response.   
From one study, Patients with heartburn symptoms are started with the trial of 
empirical high dose PPI(omeprazole), in order to evaluate the accuracy of 
detecting GERD. The results of the study showed that in patients with typical 
GERD symptoms the omeprazole test is 80% sensitive in the diagnosis of 
GERD and  fairly specific (57%). This will cut down cost on invasive 
procedures for diagnosis(71). 
The omeprazole test (OT) was used in non-cardiac chest pain patients for the 
diagnosis of GERD by Fass and colleagues (72) and reported 78% and 86%, 
sensitivity and specificity respectively for diagnosis of GERD by omeprazole 
test (OT) test in non-cardiac chest pain patients. It also revealed 59% reduction 
in the number of invasive diagnostic tests and is cost effective. 
In another study by Ours and colleagues (73) found a reliable method to 
recognize acid-related cough, with high dose PPI for 2 weeks (omeprazole 
40mg twice daily).   
The advantages of empirical PPI trial are : non-invasive, inexpensive, easy, 
office based and available to all. More it reduces the number of invasive 
procedures.  
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UPPER GI ENDOSCOPY 
Upper GI endoscopy is the standard test used for diagnosis of esophagitis, it 
also tells us the extent of involvement. It also excludes the other causes for 
symptoms. Only 20-60% of GERD patients by pH testing have esophagitis at 
upper GI endoscopy. The upper GI endoscopy has good specificity (90-95%) 
and low sensitivity(74). 
The earliest finding of acid reflux in endoscopy is erythema and edema, there 
are nonspecific and  these finding are dependent on the endoscopic quality of 
image(75). The reliable endoscopic signs are a) Friability (refers to tendency for 
easy bleeding) as a result of capillary enlargement in response to acid near the 
mucosal surface. b) Red streaks are found in the ridges of the esophageal folds, 
they have upward extension from the esophageal junction(76).  
Progressive injury by acid causes erosions which is represented by shallow 
mucosal break with exudate (yellow or white), which is surrounded by 
erythema. Most commonly erosions start at the gastroesophageal junction, 
extending across the top of mucosal folds. Erosions can be multiple depending 
on the amount and duration of acid injury. Other etiologies for erosions are 
infectious causes of esophagitis,  Nonsteroidal anti-inflammatory 
drugs(NSAIDS) and long standing smoking(74).  Esophageal ulcers depict more 
severe damage, extend deep into the mucosa or submucosa.  
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Many classifications are there for esophagitis, but none have been accepted 
worldwide. The most popular classification in Europe is the Savary-Miller 
classification(77). The Los-Angeles (LA) classification of esophagitis is being 
widely recognized  and increasing acceptance in Europe and the United 
States(78). Capsule endoscopy of the esophagus is not of much use in the 
diagnosis of GERD. 
Majority of patients with GERD are initially treated with PPI. The need for 
endoscopy arises when there is warning / alarm symptoms like GI bleeding, 
dysphagia, weight loss and odynophagia. In these situations early endoscopy is 
warranted in order to rule out varices, ulcers, infections, cancers and helps in the 
diagnosing the GERD complications like the stricture and Barrett's esophagus. 
 American college of Physicians Guidelines suggest the main role of upper GI 
endoscopy is to diagnosis GERD complications and treat them, particularly 
peptic strictures and then to define Barrett's esophagus(79).  
 Other special situations where endoscopy is recommended, classic GERD 
symptoms persisting after trial therapy of 4 to 8 weeks with high dose PPI, and 
in patient who have severe esophagitis and completed 2 months of PPI therapy 
for healing assessment and screening for Barrett's esophagus. 
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Diagnostic tests for GERD (Gastroesophageal Reflux Disease) 
Tests for Reflux 
  - Intraesophageal pH monitoring (catheter or catheter-free system) 
  - Ambulatory impedence and pH monitoring (nonacid reflux) 
  - Barium esophagogram 
Tests to Assess Symptoms 
  - Empirical trial of acid suppression 
  - Intraesophageal pH monitoring with symptom analysis 
Tests to Assess Esophageal Damage 
  - Endoscopy 
  - Wireless capsule endoscopy 
  - Esophageal biopsy 
Tests to Assess Esophageal Function 
  - Esophageal manometry 
  - Esophageal impedance 
 
 
Page | 36  
 
ENDOSCOPIC GRADING SYSTEMS FOR ESOPHAGITIS 
Savary-Miller Classification 
Grade 0    Not applicable 
Grade I     Single, erosive, or exudative lesion on one longitudinal fold 
Grade II    Multiple erosions on more than one longitudinal fold 
Grade III   Circumferential erosions  
Grade IV   Ulcer, stricture, or short esophagus, isolated or associated with 
grades I -III  
Grade V    Barrett's esophagus ± grades I through III 
 
Los Angeles Classification 
Grade A -   One or more mucosal breaks confined to folds,  ≤5mm  
Grade B -   One or more mucosal breaks > 5mm confined to folds but not 
continuous  between tops of mucosal folds 
Grade C -   Mucosal breaks continuous between tops of two or more mucosal 
folds, but not circumferential 
Grade D -   Circumferential mucosal breaks 
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ENDOSCOPIC BIOPSY OF ESOPHAGUS 
The esophageal biopsies are not done routinely. The mucosa may be normal 
endoscopically but there may be microscopic reflux changes(80). Hyperplasia 
of the basal cells and rete peg height being increased are the two features 
representing accelerated epithelial turnover, they are not specific but sensitive 
for the diagnosis of GERD(81). It is done to rule out infections, cancers, or 
bullous skin disease. The primary indications are to exclude eosinophilc 
esophagitis and to define Barrett's esophagus(82). When there is a clinical doubt 
of Barrett's esophagus, then esophageal biopsies are compulsory.  
 
REFLUX TESTING 
The standard method for diagnosing pathologic acid reflux is by ambulatory 
intraesophageal pH monitoring(83,84). In catheter based testing of pH, the 
probe is passed through the nose and is fixed 5cm above the LES which is 
determined by the manometry, and it is connected to a battery device which has 
the capacity of collecting the values of pH every 4 to 6 seconds. Patients are 
provided with event marker which can be activated when patient has symptoms, 
meals, and change in body position. The monitoring is done for 18-24 hours. 
Patient are advised to carry out their regular activities without any restrictions 
and have normal diet. When pH drops less than 4 it is called a reflux episodes. 
The following parameters are measured: total episodes of reflux in number, 
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longest reflux episode duration, number of reflux episodes more than 5 minutes, 
the percent of time when pH is below 4, percent of total time supine and upright 
when pH below 4. The most important reproducible parameter for GERD is the 
percent of total time when the pH is below 4. Ambulatory pH monitoring helps 
in detecting sleep and meal related GER, positional variations, and helps to 
correlate reflux events with symptoms. 
Major development in reflux testing are the two new technology, first is the 
catheter free system(85). It is a wireless pH capsule which is fixed to the 
mucosa of esophagus, it has a small needle with delivery system. It has a 
portable receiver that receives pH data from  the capsule. Catheter free systems 
has the advantage of extending the monitoring beyond 24 hours. This reason 
makes it the preferred method. There are no major restriction in daily activities 
and meals. PPIs should be stopped for a minimum of 7 days prior to the 
procedure. The next advancement in technology: pH testing combined with  
impedance. This combination allows measurement of acid reflux and nonacid 
(volume) reflux.   
 
BARIUM STUDY 
The barium esophagogram is an easily available, non invasive and inexpensive 
test(86). It is helpful in documenting the anatomical narrowing of the esophagus 
and demonstrating the presence of hiatal hernia and its reducibility. Some 
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conditions can be missed by upper GI endoscopy namely, minimally narrowed 
peptic strictures, Schatzki's rings and esophageal webs, which can be seen with 
an esophagogram. The barium esophagogram helps in assessment of peristalsis 
and it identifies a weak esophageal pump, and is used in preoperative 
assessment. Only moderate to severe esophagitis is picked by barium 
esophagogram, it misses mild esophagitis and Barrett's esophagus.  
 
MANOMETRY  
The invention of high resolution multichannel manometry  has transformed this 
esophagus function test. Manometry helps in assessing the relaxation and LES 
pressure, it also assess the peristaltic activity, along with amplitude, velocity 
and duration of the contractions. Esophageal manometry is not routinely needed 
in patients with  uncomplicated GERD, as many have normal LES resting 
pressure. It is recommended before antireflux surgery for assessment of 
esophageal peristalsis(83). If the manometry test finds ineffective peristalsis, 
then it is a contraindication for a complete fundoplication. Impedence testing is 
combined with manometry. The  impedance test will find out patients with 
physiologic motility defect, and these patients need a modified fundoplication.   
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COMPLICATIONS 
HEMORRHAGE, ESOPHAGEAL ULCERS AND ESOPHAGEAL  
PERFORATION 
GERD - related deaths (non- cancer) is very rare(0.46 per 1 lakh persons). The 
fatal and most common causes are ulcer perforation, hemorrhagic esophagitis, 
rupture in severe esophagitis, and aspiration pneumonia(87). Esophageal 
perforation and major hemorrhage are commonly associated with severe 
esophagitis or deep esophageal ulcers. In the era of PPI, esophageal perforation 
is very rare. If esophageal perforation occurs then it result in death. Clinically 
significant hemorrhage in GERD patients is reported in 7 to 18% of them (88) 
and can cause iron deficiency anemia.   
 
ESOPHAGEAL STRICTURES 
In patients with untreated reflux esophagitis, 7 to 23% of them have strictures. It 
is associated with chronic Non Steroidal Anti-inflammatory drugs (NSAID) use  
and most commonly seen in elderly men(89). Stricture formation is very 
complex, begins as inflammation which is reversible with edema, vascular 
congestion, cellular infiltration then is followed by deposition of collagen, 
finally resulting in fibrosis which is irreversible. dysphagia is the most common 
symptom, occurs mainly to solids, in contrary to the strictures of malignancy 
Page | 41  
 
people have good appetite, they modify their diet habits and lose less weight. 
Heart burn decreases with the formation of stricture, because it works as a 
barrier to reflux.   
Peptic strictures are located in the lower end of esophagus, they have smooth 
walls and narrow circumferentially. Strictures are predominantly less than 1 cm 
but rarely can extend till 8cm. Long strictures, which is not usual, there must be 
a suspicion for other predisposing factors, like pill esophagitis, ZE syndrome, 
and long duration of NG tube(89). Stricture in the mid or upper end of 
esophagus should be evaluated for malignancy and Barrett's esophagus. 
Schatzki's ring is thought to be an atypical manifestation of early peptic 
stricture. All strictures should be biopsied to rule out Barret's esophagus and 
malignancy. 
 
BARRETT'S ESOPHAGUS 
Barrett's esophagus is a known complication of chronic reflux disease. It is a pre 
malignant condition. It predisposes to malignancy. It is condition in which the 
distal esophagus squamous epithelium is replaced by abnormal columnar 
epithelium. The long standing acid reflux injures the squamous epithelium in 
the distal esophagus, healing occurs by metaplastic process, replacement of the 
injured squamous epithelium by columnar epithelium. It is a risk factor for 
malignancy (adenocarcinoma of the esophagus). 
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TREATMENT 
The therapeutic goal in patients without esophagitis is to relieve symptoms and 
prevent relapses. The goal in patients with esophagitis is to relieve the reflux 
symptoms and heal the esophagitis, thereby preventing further complications 
and relapses. 
Even though GERD prevalence is high, many affected persons do not seek 
professional care, they self-medicate with OTC histamin-2 receptor antagonist 
(H2RAs), antacids and PPIs.  
 
"ICEBERG" MODEL 
GERD population can be compared with the "iceberg" model,  the huge 
majority of the affected persons are invisible because they do not seek medical 
care and self-medicate with OTC. The tip of the iceberg is represented by 
patients with complications or severe symptoms, who are seen by 
professionals(90). 
 
LIFESTYLE MODIFICATIONS 
Lifestyle modifications should be included in the initial plan of management. It 
should be explained to patients. Lifestyle modifications are helpful for patients 
with intermittent and mild symptoms. Lifestyle modifications include reducing 
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weight, avoiding tight-fitting clothes, cessation of smoking and alcohol, head-
of-the-bed elevation, avoiding night bedtime snacks, making dietary changes, 
and not lying down immediately after meals. Studies showed that the above 
methods, reduce acid related-reflux events, increase esophageal acid clearance 
and can relieve heartburn symptoms(91). 
 Nocturnal reflux episodes are reduced by avoiding night time snacks and 
having dinner several hours before going to bed. Losing weight and avoiding 
tight-fitting clothes help in decreasing the reflux by the "abdominal stress" 
mechanism. Weight gain is related to increase in the reflux symptoms(92). 
Reduction in alcohol and cessation of smoking is useful in decreasing the 
incidence of reflux symptoms, because both reduce acid clearance, lower LES 
pressure and impairs the protective function of the squamous epithelium. 
Avoiding heavy meals, chocolates and fats decrease reflux frequency by 
decreasing lowering LES pressure and decreasing episodes of tLESRs. Some 
patients have heartburn after the intake of spicy food, tea, coffee, citrus drinks, 
cola drinks and tomato based products; the postulated reason for these 
symptoms are stimulation of acid secretion in the stomach or sensitivity to low 
pH in the esophagus(91). Food prohibition should be fitted according to 
individuals sensitivity rather than indiscriminate food prohibition, this promotes 
compliance. Patients should avoid medicine that lower the LES pressure, if 
possible. The drugs which decrease the LES pressure are Theophylline, 
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morphine, dopamine, calcium channel blockers, diazepam etc. Drugs like 
bisphosphonates can cause local esophagitis.  In one evidence- based 
review(90), it was found that intake of fatty foods, citrus products, chocolate, 
smoking and alcohol have strong relation that their intake can worsen the reflux 
as  documented by pH testing. However cessation of these products improved 
symptoms, but there are only little evidence. Head end elevation of bed, weight 
loss and left lateral position showed improvement in symptoms of GERD in 
case-control studies(90). 
 
ANATACID AND OVER-THECOUNTER MEDICATIONS 
Over-the-counter medications are used in treatment of mild and infrequent 
heartburn. Antacids are commonly used, they work by increasing the LES 
pressure and buffers the gastric acid. It works only for a short duration. 
Heartburn can be relieved immediately, but patient have to take it frequently. 
Gaviscon is made up of alginic acid and antacids, It acts as a mechanical barrier, 
Gaviscon comes in contact with saliva it forms a highly viscous solution which 
floats on the gastric contents. From studies gaviscon and antacids are effective 
in relieving heartburn symptoms when compared with a placebo. Trials on long 
term therapy show only 20% of patients have symptom relief(93). Both 
gaviscon and antacids are not useful in healing esophagitis. OTC H2RAs have 
no role in healing esophagitis, onset of symptom relief is slow when compared 
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with antacids and can relieve heartburn symptoms for more than 6 hours to 10 
hours(94). PPIs are also available OTC.  
 
HISTAMINE-2 RECEPTOR ANTAGONIST (H2RAs) 
The H2RAs include ranitidine, cimetidine, nizatidine and famotidine. These 
drugs are useful in controlling nocturnal acid-secretion when compared with 
acid-secretion related to meal, the reason being postprandially the parietal cells 
are stimulated by gastrin with help of histamine and acetylcholine(95).  All four 
drugs when used in adequate doses are equally effective, usually given before 
food twice daily. From trials it is evident that H2RAs when compared with 
placebo, H2RAs can significantly decrease the heartburn symptoms. 
A meta-analysis showed that H2RAs rarely exceeded 60% in overall esophagitis 
healing rates, even at higher doses and prolonged therapy up to 12 weeks(96). 
Based on the severity of esophagitis the healing rates varied: 60-90% healing 
rates for grade I and II esophagitis, 30-50% haealing rates in grade III and IV 
esophagitis(96). 
From several studies, PPI is superior to H2RAs. Patients on PPI therapy have 
nocturnal gastric acid breakthrough, in some patients it produces reflux 
symptoms. From one study, it showed that H2RAs given at night eliminated this 
nocturnal gastric acid breakthrough. This made the re-entry of H2RAs in the 
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PPI era(97). The limitations of the study was that it did not mention on the 
tolerance of the H2RAs which develops over week of therapy.  
The H2RAs have minor side effects which are reversible, and are very safe 
drugs. It has a side effect rate of around 4%. Drug interactions were documented 
with cimetidine and to a lesser extent with ranitidine. Serum concentration of 
drugs like theophylline, phenytoin, warfarin and procainamide are increased 
after cimetidine administration, and to a lesser extent with ranitidine. Drug 
interactions are not reported with nizantidine and famotidine. 
 
PROTON PUMP INHIBITORS 
The PPIs include omeprazole, pantoprazole, lansoprazole and esomeprazole. 
The PPIs inhibit acid-secretion to a greater extent than the H2RAs.They inhibit 
both nocturnal and meal-related acid-secretion, they don't make the patient 
achlorhydric. Acid inhibition is delayed after oral intake, the reason being PPI 
has to accumulate in the secretory canaliculus of parietal cells, in order to bind 
with the actively secreting proton pumps irreversibly(98).  PPI are given before 
meal, because most of the proton pumps are active.  
PPIs are far superior in relieving heartburn symptoms completely, within one or 
two weeks, when compared with H2RAs in severe GERD patients(96). Efficacy 
wise PPIs are superior when compared with H2RAs. PPIs have the ability to 
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keep the intragastric pH above 4, for more than 10 to 14 hours. In contrary 
H2RAs can maintain the intragastric pH above 4, for only 6 to 8 hours(99,100). 
A Cochrane meta-analysis found PPI therapy superior to H2RAs and placebo in 
patient with non-erosive reflux disease and in primary care for undiagnosed 
reflux symptoms. It also showed that 20-30% reduced effect than in patients 
with esophagitis(101).   
Large meta-analysis and controlled studies have found that more than 80% of 
patients on PPIs for eight weeks have complete healing of ulcerative 
esophagitis, when compared with H2RAs it is 51% and 28% for placebo(96, 
102,103). 
 Another Cochrane review of 26 trials (104) with 4064 patients, PPIs were 
found to be superior in healing esophagitis at 4-8 weeks when compared with 
H2RAs. In patient whom the esophagitis has not healed, increasing the dose of 
PPI or prolonged treatment with the same dose showed 100% healing. 
Among the PPIs, the newer PPI esomeprazole was found to superior in healing 
esophagitis when compared with omeprazole and lansoprazole from one large 
study(105). Another meta-analysis compared esomeprazole with the other PPIs 
and showed that the therapeutic advantage was high with severe grades of 
esophagitis (grade C and D - LA classification) and minimal with less severe 
grades of esophagitis (grade A and B - LA classification). Esomeprazole has 
highest systemic bioavailability.   
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The common side effects of PPIs are diarrhea and headaches. These drugs are 
tolerated well. Fasting serum gastrin levels are elevated with all PPIs, but do not 
cross the normal range. Gastrin levels normalize within four weeks of 
discontinuation of the PPI. Drug interactions, warfarin and diazepam clearance 
is decreased with ompeprazole therapy, the reason being all competing for 
cytochrome P-450 isoenzyme. Newer PPIs have very minor or nil drug 
interactions.   
 
MAINTENANCE THERAPIES 
In patients with decreased LES pressure, difficult to manage symptoms and 
severe esophagitis may have a chronic relapsing course of GERD(93). Once 
healing of esophagitis is completed, and medications are stopped, recurrence 
occurs within 6 months in more than 80% of patient with severe disease, and 
around 15 % to not more than 30% of patients with milder esophagitis(106). 
Cochrane review found that PPIs are superior than H2RAs in keeping the 
remission of disease over six to twelve months(107).  The relapse rate for 
esophagitis among 10 randomized control trails was 22% for patient on PPI and 
58% for patient on H2RAs. Many patient with severe GERD ( severe 
esophagitis, daily symptoms, or complications) are put indefinitely on chronic 
PPI treatment by their physicians.   
 
Page | 49  
 
PROKINETIC DRUGS 
In United States three prokinetic drugs are available for the treatment of GERD. 
The three drugs are: metoclopramide, which is a dopamine antagonist; 
bethanechol,  cholinergic agonist; and other drug is a serotonin (5-HT4) 
receptor agonist, cisapride. These drugs increase acid clearance, increase gastric 
emptying and increase the LES pressure thereby improve the reflux symptoms. 
These drugs does not alter the tLESRs. Their efficacy is decreased with 
increasing severity of the disease(108). The efficacy of prokinetic drugs in 
healing of esophagitis is not reliable.  The use of these prokinetic drugs are 
limited, because of their side-effects. The side effects of bethenechol include 
headache, urinary frequency, flushing, abdominal cramps and blurred vision. 
Metoclopramide, a dopamine antagonist, crosses the blood-brain barrier, causes 
fatigue, restlessness, lethargy, and anxiety. Metoclopramide can rarely cause 
parkinsonism, dystonia, tremors, tardive dyskinesia most commonly occur in 
elderly patients. By using sustained release tablet or reducing the dose, side 
effects can be reduced. Dopmperidone does not cross the blood-brain barrier, is 
another dopamine antagonist, with less side effects. Cisapride has been stopped 
in United States, reports showed severe cardiac arrhythmias, cardiac arrest and 
deaths, reason being possible interactions with other drugs(109).  
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TRANSIENT LES RELAXATION INHIBITORS 
Baclofen is the only drug known to decrease the tLESRs. Baclofen is a GABAB 
agonist. Its main clinical use was in treatment of spasticity. Baclofen in doses of 
5-20mg three times a day for four weeks to months, improves reflux symptoms 
by decreasing the tLESR and also reduces the acid and duodenal reflux(110). 
Tolerance is an important issue. Side effects of baclofen are nausea, dizziness, 
vomiting and drowsiness, 20% of patients discontinued therapy because of the 
side effects.  
 
ANTIREFLUX SURGERY 
Surgical fundoplication is the only way to correct the factors causing GERD and 
the need for long term medications is eliminated. Antireflux surgery decreases 
GER by decreasing the episodes of tLESRs, increasing basal LES pressure, and 
by inhibiting complete LESR(111). Antireflux surgeries are done by hiatal 
hernia reduction in to the abdomen, reinforcing the LES and reconstruction of 
the diaphragmatic hiatus(112). Three most popular surgeries, before the era of 
laparoscopy, were the Belsey Mark IV repair, Nissen fundoplication, and HILL 
posterior gastropexy. After the invention of laparoscopy, minimally invasive 
procedures are possible, two most common surgeries are the Toupet partial 
fundoplication, and the Nissen 360-degree fundoplication. The Nissen 360-
degree fundoplication has longer durability and is considered as a superior 
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procedure. The side effects of the procedure are postoperative bloating 
symptoms and dysphagia(113). Patient with severe GERD and a short 
esophagus with a large non reducible hernia, long segment Barrett's esophagus, 
or a tight stricture, will need a Collins lengthening operation. 
In a systematic review involving 449 patients of 6 randomized trials, comparing 
laparoscopic fundoplication with open fundoplication, it showed lower 
operative morbidity with laparoscopic fundoplication and shorter stay at 
hospital(114). Recurrence rates were equal between the procedures, no 
significant difference was observed.  
Anti reflux surgery can be considered in the following settings: a) healthy 
patient whose symptoms are under control with PPI therapy, who has poor 
compliance to therapy, who  desires for alternative treatment due to high cost of 
long term medical treatment. b)patient with aspiration symptoms and who have 
volume regurgitation , not improvement with PPI therapy. c)young patients with 
recurrence of strictures. 
Preoperative tests are necessary for antireflux surgery. Upper GI endoscopy is 
done to rule out Barrett's esophagus, strictures, and carcinoma or dysplasia. 
Barium esophagogram helps in identification of short esophagus, hiatal hernia 
which is not reducible, and also assess the esophageal motility.  A weak 
esophageal pump is identified by esophageal manometry. Patients not 
responding to PPI therapy should undergo 24 hours pH testing. In some patients 
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fasting gastrin levels and gastric acid secretion assessment may be necessary. A 
complete assessment prior to surgery can help in modification of original 
surgery or to make an alternative diagnosis in around 30% of patients(115).  
Antireflux surgery relieve the symptoms and decreases the requirement of 
dilation procedures for strictures in more than 90% patients, but there is no 
change in the risk of development of esophageal cancer(116). From two large 
studies, antireflux surgery (both open and laparoscopy) was not superior to the 
medical therapy with PPIs.  
Antireflux surgery is not permanent cure. Failure of antireflux sugery has been 
increasing. The common reasons for failure of fundoplication are herniation into 
the chest, malpositioned or a tight fundoplication, and paraesophageal hernia 
through an intact fundoplication.  
 
NEWER THERAPIES 
Magnetic sphincter, it consists of a necklace made of titanium beads with 
magnetic cores, minimal dissection of hiatus is done and it is placed around the 
cardia. The magnetic forces augment the LES when the esophagus is at rest, to 
prevent the reflux. The device is weak because it permits peristalsis with 
swallowing to open the magnetic device(117). In a study of 100 GERD patients, 
93% of patients have reduced their use of PPI by 50%, 64% of patients the acid 
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reflux values normalized,  92% of patient had improved quality of life. 
Dysphagia was common. Six patients removed their device, three had severe 
dysphagia which made them remove the device. 
Electrical stimulation to the LES is a new technique, which is found to improve 
the pressure of LES. LES relaxation is not affected. Bipolar lead with stitch 
electrodes are placed laparoscopically in the muscularis propria of LES, which 
is connected to a pulse generator on the anterior abdomen(118). Results from a 
small study were satisfactory. The patients did not have dysphagia. Large group 
study with monitoring and follow up is needed in order to make it an available 
treatment option for GERD.   
 
TREATMENT FOR STRICTURES 
Dysphagia in stricture patients, are dependent on the severity of esophagitis and 
the diameter of the stricture(119). Dysphagia is common when the lumen 
diameter of esophagus is less than 13mm. Esophageal dilation is required for 
symptomatic patients. For short and simple strictures, dilation can be done by 
peroral blind passage of rubber Hurst (it has rounded ends) or mercury-filled 
Maloney (tapered ends)dilators of various sizes. Long, irregular, tighter and 
complicated strictures, requires bougienage with the help of a guidewire using 
balloon (Gruentzig) dilators or Savary, hollow-centered, plastic dilators(120). 
The treatment of esophageal strictures has been greatly impacted by the use of 
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PPI. In a study among patients with strictures, it showed PPIs superior to 
H2RAs in reducing heartburn and dysphagia, and also reduced the cost of 
treatment and decreased the need for repeated dilations(121). Many studies 
showed an approximate 33% drop in the incidence of recurrent esophageal 
strictures. This marked decrease in the strictures is parallel to the increasing use 
of PPIs(122). Strictures not responding even after dilation may require stents or 
steroids. Intralesional injection of steroids prevent deposition of  collagen and 
help in its breakdown, and reduces formation of scar. Self -expanding plastic 
stents have more expansive force than metal stents which decreases the 
migration. After 3 months stents are removed. Most common complication of 
stents is the stent migration, which occurs in around 1% of patients.   
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OBSERVATION AND RESULTS 
This cross sectional observational study was conducted at PSG institute of 
Medical Sciences and Research, Peelamedu, Coimbatore from February 2016 to 
July 2017. A total of 100 patients, diagnosed of Gastro-esophageal reflux 
disease (GERD) based on UGI scopy was enrolled in this study. Descriptive 
statistics of the collected data of total 100 patients was analyzed. Mean age of 
GERD patients was 56.09 ± 15.93 years (Range: 20 – 82 years). Furthermore, 
we divided the total of 100 GERD patients into two groups: GERD with 
complications (24 patients) and GERD without complications (76 patients) and 
analyzed the documented variables between these two groups. Mean age of 
GERD with complications was 67 ± 11.53 years (Range: 41 – 82 years) and 
mean age of GERD without complications was 52.64 ± 15.57 years (Range: 20 
– 82 years).  Final results were interpreted in tables and /or illustrative graphs as 
follows. Values expressed as A (B %), represents actual numbers as A and 
percentage as B%. Demographic parameters analyzed were age, sex and BMI of 
the patients. Lifestyle parameters assessed were smoking, alcohol, spicy food, 
fried food, intake of meat, tea / coffee, citrus fruits, aerated drinks, heavy meals, 
sleep disturbances and effect on daily work.  Clinical symptoms evaluated were 
heartburn, regurgitation, retrosternal chest pain, dysphagia, odynophagia, 
positional variation of these symptoms. In addition, presence of Helicobacter 
pylori, GERD grades and its complications were also analyzed. 
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TABLE 1: SEX DISTRIBUTION IN GERD PATIENTS 
SEX 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
MALE 75 75 
FEMALE 25 25 
TOTAL 100 100 
 
GRAPH 1: SEX DISTRIBUTION IN GERD PATIENTS 
 
 In the present study, out of 100 GERD patients, 75 patients were males (75%) 
and 25 patients were females (25%) with male to female ratio of 4:1. 
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TABLE 2: BODY MASS INDEX DISTRIBUTION IN GERD PATIENTS 
BODY MASS INDEX 
(BMI) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
 < 25 70 70 
≥ 25 30 30 
TOTAL 100 100 
 
GRAPH 2: BODY MASS INDEX DISTRIBUTION IN GERD PATIENTS 
 
 In this study, among 100 GERD patients, body mass index was < 25 in 70 
patients(70%) and  ≥ 25 in 30 patients (30%). 
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TABLE 3: DISTRIBUTION OF CO-MORBITIES IN GERD PATIENTS 
NUMBER OF 
COMORBIDITIES 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
< 3 48 48 
≥ 3 21 21 
ABSENT 31 31 
TOTAL 100 100 
 
GRAPH 3: DISTRIBUTION OF CO-MORBITIES IN GERD PATIENTS 
 
 In the current study, amongst 100 GERD patients, 31 patients didn’t have                            
co-morbidities (31%), 48 patients (48%) had < 3 co-morbidities and 21 
patients(21%) had ≥ 3 co-morbidities. 
Page | 59  
 
TABLE 4: DISTRIBUTION OF HEARTBURN IN GERD PATIENTS 
HEARTBURN 
(EPISODES) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
≤ 2 / WEEK 11 11 
>2 / WEEK 41 41 
DAILY 22 22 
ABSENT 26 26 
TOTAL 100 100 
 
GRAPH 4: DISTRIBUTION OF HEARTBURN IN GERD PATIENTS 
 
 In our study, amongst 100 GERD patients, heartburn symptom was absent in 
26 patients(26%), daily episodes in 22 patients (22%), > 2 episodes /week in 41 
patients (41%) and ≤  2 episodes / week in 11 patients (11%).  
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TABLE 5: REGURGITATION DISTRIBUTION IN GERD PATIENTS 
REGURGITATION 
(EPISODES) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
≤ 2 / WEEK 31 31 
>2 / WEEK 25 25 
DAILY 19 19 
ABSENT 25 25 
TOTAL 100 100 
 
GRAPH 5: REGURGITATION DISTRIBUTION IN GERD PATIENTS 
 
 In this study, among 100 GERD patients, regurgitation was absent in 25 
patients(25%), daily episodes in 19 patients (19%), > 2 episodes /week in 25 
patients (25%) and ≤  2 episodes / week in 31 patients (31%).  
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TABLE 6: RETROSTERNAL CHEST PAIN DISTRIBUTION  
RETROSTERNAL 
CHEST PAIN 
(EPISODES) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
≤ 2 / WEEK 32 32 
>2 / WEEK 9 9 
DAILY 25 25 
ABSENT 34 34 
TOTAL 100 100 
 
GRAPH 6: RETROSTERNAL CHEST PAIN DISTRIBUTION 
 
In our study, out of 100 GERD patients, retrosternal chest pain was absent in 34 
patients(34%), daily episodes in 25 patients (25%), > 2 episodes /week in 9 
patients (9%) and ≤  2 episodes / week in 32 patients (32%).  
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TABLE 7: DISTRIBUTION OF DYSPHAGIA IN GERD PATIENTS 
DYSPHAGIA 
(EPISODES) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
≤ 2 / WEEK 5 5 
>2 / WEEK 3 3 
DAILY 17 17 
ABSENT 75 75 
TOTAL 100 100 
 
GRAPH 7: DISTRIBUTION OF DYSPHAGIA IN GERD PATIENTS 
 
 In this study, among 100 GERD patients, dysphagia was absent in 75 
patients(75%), daily episodes in 17 patients (17%), > 2 episodes /week in 3 
patients (3%) and ≤  2 episodes / week in 5 patients (5%).  
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TABLE 8: DISTRIBUTION OF ODYNOPHAGIA IN GERD PATIENTS  
ODYNOHAGIA 
(EPISODES) 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
≤ 2 / WEEK 1 1 
>2 / WEEK 3 3 
DAILY 14 14 
ABSENT 82 82 
TOTAL 100 100 
 
GRAPH 8: DISTRIBUTION OF ODYNOPHAGIA IN GERD PATIENTS 
 
In our study, out of 100 GERD patients, odynophagia was absent in 82 
patients(82%), daily episodes in 14 patients (14%), > 2 episodes /week in 3 
patients (3%) and ≤  2 episodes / week in 1 patient (1%).  
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TABLE 9: DISTRIBUTION OF POSITIONAL VARIANTION OF 
SYMPTOMS IN GERD PATIENTS 
POSITIONAL 
VARIATION OF 
SYMPTOMS 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 25 25 
ABSENT 75 75 
TOTAL 100 100 
 
GRAPH 9: DISTRIBUTION OF POSITIONAL VARIANTION OF 
SYMPTOMS IN GERD PATIENTS  
 
 In our study, amongst 100 GERD patients, history of positional variation of 
GERD symptoms was present in 25 patients (25%) and absent in 75 
patients(75%).  
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TABLE 10:SMOKING HISTORY DISTRIBUTION IN GERD PATIENTS 
SMOKING 
HISTORY 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 52 52 
ABSENT 48 48 
TOTAL 100 100 
 
GRAPH10:SMOKING HISTORY DISTRIBUTION IN GERD PATIENTS 
 
 In the present study, out of 100 GERD patients, smoking history was present in 
52 patients (52%) and absent in 48 patients (48%). We regarded positive history 
of smoking as ≥ 2 cigarettes / week. 
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TABLE 11: DISTRIBUTION OF ALCOHOL HISTORY IN GERD  
ALCOHOL 
HISTORY 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 44 44 
ABSENT 56 56 
TOTAL 100 100 
 
GRAPH 11: DISTRIBUTION OF ALCOHOL HISTORY IN GERD 
 
 In this study, among 100 GERD patients, alcohol history was present in 56 
patients (56%) and absent in 44 patients (44%). We regarded positive history of 
alcohol as ≥ 90 ml / month. 
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TABLE 12: VEGETARIAN VS NON VEGETARIAN DISTRIBUTION 
VEG VS NON VEG 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
VEG 25 25 
NON VEG 75 75 
TOTAL 100 100 
 
GRAPH 12: VEGETARIAN VS NON VEGETARIAN DISTRIBUTION 
 
 In the present study, out of 100 GERD patients, 25 patients (25%) were 
vegetarians and 75 patients (75%) were non vegetarians. We regarded patients 
as non-vegetarian, upon intake of any kind of meat at frequency of ≥ 1 / week. 
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TABLE 13: DISTRIBUTION OF SPICY FOODS INTAKE IN GERD  
INTAKE OF    
SPICY FOODS 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 59 59 
ABSENT 41 41 
TOTAL 100 100 
 
GRAPH 13: DISTRIBUTION OF SPICY FOODS INTAKE IN GERD 
 
 In this study, among 100 GERD patients, history of spicy food intake was 
present in 59 patients (59%) and absent in 41 patients (41%). We regarded 
positive history of spicy food intake as ≥ 1 / week. 
 
Page | 69  
 
TABLE 14: DISTRIBUTION OF FRIED FOODS INTAKE IN GERD  
INTAKE OF     
FRIED FOODS 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT  26 26 
ABSENT 74 74 
TOTAL 100 100 
 
GRAPH 14: DISTRIBUTION OF FRIED FOODS INTAKE IN GERD 
 
 In the present study, out of 100 GERD patients, history of fried foods intake 
was present in 26 patients (26%) and absent in 74 patients (74%). We regarded 
positive history of fried food intake as ≥ 1 / week. 
. 
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TABLE 15: DISTRIBUTION OF CITRUS FRUITS INTAKE IN GERD  
INTAKE OF    
CITRUS FRUITS 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 13 13 
ABSENT 87 87 
TOTAL 100 100 
 
GRAPH 15: DISTRIBUTION OF CITRUS FRUITS INTAKE IN GERD 
 
 In the current study, amongst 100 GERD patients, history of citrus fruits intake 
was present in 13 patients (13%) and absent in 87 patients (87%). We regarded 
positive history of citrus fruits intake as ≥ 1 / week. 
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TABLE 16: DISTRIBUTION OF TEA / COFFEE INTAKE IN GERD  
TEA / COFFEE 
INTAKE 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
< 3 CUPS / DAY 17 17 
≥ 3 CUPS / DAY 39 39 
ABSENT 44 44 
TOTAL 100 100 
 
GRAPH 16: DISTRIBUTION OF TEA / COFFEE INTAKE IN GERD 
 
 In the present study, out of 100 GERD patients, history of tea / coffee intake 
was absent in 44 patients (44%), frequent intake in 39 patients (39%) and 
infrequent intake in 17 patients (17%). 
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TABLE 17: DISTRIBUTION OF AERATED DRINKS INTAKE IN GERD 
AERATED DRINKS 
INTAKE  
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
< 5 DRINKS / WEEK 3 3 
≥ 5 DRINKS / WEEK 4 4 
ABSENT 93 93 
TOTAL 100 100 
 
GRAPH 17:DISTRIBUTION OF AERATED DRINKS INTAKE IN GERD 
 
 In the current study, amongst 100 GERD patients, history of aerated drinks 
intake was absent in 93 patients (93%), frequent intake in 4 patients (4%) and 
infrequent intake in 3 patients (3%). 
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TABLE 18: DISTRIBUTION OF HEAVY MEAL INTAKE IN GERD  
HEAVY MEAL 
INTAKE  
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT  33 33 
ABSENT 67 67 
TOTAL 100 100 
 
GRAPH 18: DISTRIBUTION OF HEAVY MEAL INTAKE IN GERD 
 
 In the present study, out of 100 GERD patients, history of heavy meal intake 
was present in 33 patients (33%) and absent in 67 patients (67%). We regarded 
positive history of heavy meal intake as ≥ 3 plates of food in a single meal / 
week. 
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TABLE 19: DISTRIBUTION OF SLEEP DISTURBANCE IN GERD  
SLEEP 
DISTURBANCE 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT 32 32 
ABSENT 68 68 
TOTAL 100 100 
 
GRAPH 19: DISTRIBUTION OF SLEEP DISTURBANCE IN GERD 
 
 In our study, among 100 GERD patients, history of sleep disturbance due to 
either of the clinical symptoms was present in 32 patients (32%) and absent in 
68 patients (68%).  
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TABLE 20: DISTRIBUTION OF EFFECT ON WORK DUE TO GERD  
EFFECT ON WORK  
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT  9 9 
ABSENT 91 91 
TOTAL 100 100 
 
GRAPH 20: DISTRIBUTION OF EFFECT ON WORK DUE TO GERD 
 
 In the current study, out of 100 GERD patients, history of effect on work due to 
GERD symptoms was present in 9 patients (9%) and absent in 91 patients 
(91%).  
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TABLE 21: DISTRIBUTION OF H.PYLORI IN GERD PATIENTS 
H.PYLORI  
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
PRESENT  37 37 
ABSENT 63 63 
TOTAL 100 100 
 
GRAPH 21: DISTRIBUTION OF H.PYLORI IN GERD PATIENTS 
 
 In the current study, out of 100 GERD patients, H.pylori was presenr in 37 
patients (37%) and absent in 63 patients (63%).  
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TABLE 22: DISTRIBUTION OF GRADES OF REFLUX ESOPAHGITIS 
REFLUX 
ESOPHAGITIS 
GRADES 
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
GRADE A  57 57 
GRADE B 14 14 
GRADE C 17 17 
GRADE D 12 12 
TOTAL 100 100 
 
GRAPH 22: DISTRIBUTION OF REFLUX ESOPHAGITIS GRADES 
 
 
 In our study, amongst 100 GERD patients, 57 patients (57%) belongs to Grade 
A, 14 patients (14%) belongs to Grade B, 17 patients (17%) belongs to Grade C 
and 12 patients (12%) belongs to Grade D.  
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TABLE 23: DISTRIBUTION OF COMPLICATONS OF GERD 
GERD 
COMPLICATIONS  
DISTRIBUTION (N=100) 
NUMBER PERCENTAGE 
ESOPHAGEAL 
ULCER 
12 12 
BARRETT’S 
ESOPHAGUS 
6 6 
ESOPHAGEAL 
STRICTURE 
6 6 
ABSENT 76 76 
TOTAL 100 100 
 
GRAPH 23: DISTRIBUTION OF COMPLICATONS OF GERD 
 
 In the current study, out of 100 GERD patients, 12 patients (12%) had 
esophageal ulcers, 6 patients (6%) had Barrett’s esophagus, 6 patients (6%) had 
esophageal stricture and 76 patients (76%) didn’t have complications.  
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TABLE 24: DEMOGRAPHIC VARIABLES BETWEEN GERD WITH 
COMPLICATIONS AND WITHOUT COMPLICATIONS 
DEMOGRAPHIC 
PARAMETERS 
INDEPENDENT ‘t’ TEST 
COMPLICATION 
MEAN ± SD 
WITHOUT 
COMPLICATION 
MEAN ± SD 
P value 
AGE 67.00 ± 11.78 52.64 ± 15.68 0.000* 
BMI 23.00 ± 3.42 23.42 ± 4.19 0.657 
 CHISQUARE TEST 
SEX 
67% MALES 
33% FEMALES 
78% MALES 
22% FEMALES 0.279 
 
* P= < 0.05 IS STATISTICALLY SIGNIFICANT 
 Age of the patient showed significant statistical association between 
GERD with complication group vs GERD without complication group. 
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GRAPH 24: ROC ANALYSIS: AGE OF PATIENT IN RELATION TO 
THE PRESENCE OF COMPLICATIONS OF GERD 
 
PARAMETER CUT OFF AUROC SENSITIVITY SPECIFICITY 
AGE ≥ 58.5 0.769 83% 61% 
 
In the present study, ROC analysis of age of the patient between GERD with 
complication and without complication groups showed maximum area under the 
curve of 0.769 at cutoff of ≥ 58.5 years with sensitivity of 64% and specificity 
of 58%. This implies that we can reliably predict the presence of complications 
in GERD patients of age ≥ 58.5 years. 
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TABLE 25: CLINICAL VARIABLES BETWEEN GERD WITH 
COMPLICATIONS AND WITHOUT COMPLICATIONS 
CLINICAL 
PARAMETERS 
INDEPENDENT ‘t’ TEST 
GERD WITH 
COMPLICATION 
MEAN ± SD 
WITHOUT 
COMPLICATION 
MEAN ± SD 
P 
value 
NUMBER OF        
CO-MORBIDITY 
1.67 ± 1.30 1.38 ± 1.38 0.375 
 CHISQUARE TEST 
HEART BURNS 
0% < 2 /WK 
17 % ≥  2 /WK 
83% DAILY 
0% ABSENT 
14 % < 2 /WK 
49 % ≥  2 /WK 
3% DAILY 
34% ABSENT 
0.018* 
REGURGITATION 
0% < 2 /WK 
25 % ≥  2 /WK 
75% DAILY 
0% ABSENT 
41% < 2 /WK 
25% ≥  2 /WK 
1% DAILY 
33% ABSENT 
0.023* 
RETROSTERNAL 
CHEST PAIN 
0% < 2 /WK 
17 % ≥  2 /WK 
83% DAILY 
0% ABSENT 
42 % < 2 /WK 
7 % ≥  2 /WK 
6% DAILY 
45% ABSENT 
0.016* 
DYSPHAGIA 
0% < 2 /WK 
13% ≥  2 /WK 
54% DAILY 
29% ABSENT 
7 % < 2 /WK 
0 % ≥  2 /WK 
4% DAILY 
89% ABSENT 
0.025* 
ODYNOPHAGIA 
0% < 2 /WK 
13% ≥  2 /WK 
58% DAILY 
29% ABSENT 
1 % < 2 /WK 
0 % ≥  2 /WK 
0% DAILY 
99% ABSENT 
0.035* 
POSITIONAL 
VARIATION OF 
SYMPTOMS 
25% PRESENT 
75% ABSENT 
25% PRESENT 
75% ABSENT 
1.000 
 
* P= < 0.05 IS STATISTICALLY SIGNIFICANT 
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 Heart burns, regurgitation, retrosternal chest pain showed significant 
statistical association between GERD with complication group vs GERD 
without complication group.  
 Although dysphagia and odynophagia showed p value of < 0.05, they 
didn’t exhibit strong association between these two groups due to lower 
likelihood ratio of 47.84 and 62.38 respectively. 
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TABLE 26: LIFESTYLE VARIABLES BETWEEN GERD WITH 
COMPLICATIONS AND WITHOUT COMPLICATIONS 
LIFESTYLE 
PARAMETERS 
CHISQUARE TEST 
GERD WITH 
COMPLICATION 
GERD WITHOUT 
COMPLICATION 
P value 
SMOKING 
50% PRESENT 
50% ABSENT 
53% PRESENT 
47% ABSENT 
0.822 
ALCOHOL 
37% PRESENT 
63% ABSENT 
46% PRESENT 
54% ABSENT 
0.462 
VEG VS NONVEG 
37% VEG 
63% NON VEG 
21% VEG 
79% NON VEG 
0.105 
SPICY FOODS 
50% PRESENT 
50% ABSENT 
62% PRESENT 
38% ABSENT 
0.304 
FRIED FOODS 
29% PRESENT 
71% ABSENT 
25% PRESENT 
75% ABSENT 
0.685 
CITRUS FRUITS 
4% PRESENT 
96% ABSENT 
16% PRESENT 
84% ABSENT 
0.140 
 
* P= < 0.05 IS STATISTICALLY SIGNIFICANT 
 
 Neither of the above mentioned lifestyle parameters showed statistical 
significance between these two groups. 
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TABLE 27: LIFESTYLE VARIABLES BETWEEN GERD WITH 
COMPLICATIONS AND WITHOUT COMPLICATIONS 
LIFESTYLE 
PARAMETERS 
CHISQUARE TEST 
GERD WITH 
COMPLICATION 
GERD WITHOUT 
COMPLICATION 
P value 
TEA / COFFEE 
38% FREQUENT 
16%INFREQUENT 
46% ABSENT 
39% FREQUENT 
18%INFREQUENT 
43% ABSENT 
0.978 
AERATED DRINKS 
0% FREQUENT 
0%INFREQUENT 
100% ABSENT 
5% FREQUENT 
4%INFREQUENT 
91% ABSENT 
0.305 
HEAVY MEALS 
71% PRESENT 
29% ABSENT 
34% PRESENT 
66% ABSENT 
0.647 
SLEEP 
DISTURBANCE 
71% PRESENT 
29% ABSENT 
33% PRESENT 
67% ABSENT 
0.733 
EFFECT ON WORK 
4% PRESENT 
96% ABSENT 
11% PRESENT 
89% ABSENT 
0.343 
 
* P= < 0.05 IS STATISTICALLY SIGNIFICANT 
 
 Neither of the above mentioned lifestyle parameters showed statistical 
significance between these two groups. 
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TABLE 27: ANALYSIS OF REFLUX ESOPHAGITIS GRADES AND 
H.PYLORI BETWEEN WITH COMPLICATIONS                                       
AND WITHOUT COMPLICATIONS 
PARAMETERS 
CHISQUARE TEST 
GERD WITH 
COMPLICATION 
GERD WITHOUT 
COMPLICATION 
P value 
H.PYLORI 
83% PRESENT 
17% ABSENT 
22% PRESENT 
78% ABSENT 
0.000* 
REFLUX 
ESOPHAGITIS 
GRADES 
0% A 
8% B 
46%C 
46% D 
75% A 
16% B 
8%C 
1% D 
0.000* 
 
* P= < 0.05 IS STATISTICALLY SIGNIFICANT 
 
 Presence of H.pylori showed significant statistical association between 
GERD with complication group vs GERD without complication group.  
 Although grades of reflux esophagitis showed p value of < 0.05, it didn’t 
exhibit strong association between these two groups due to lower 
likelihood ratio of 69.77. 
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DISCUSSION 
In our study, we found that out of 100 GERD patients, 75% were males and 
25% were females with male to female ratio of 4:1. Our findings were in 
contrary to previous meta-analysis study by Kim YS et al(123), who inferred 
that GERD affects more frequent in women than men.  
In this present study, we found that 70% of the patients had BMI < 25 and 30% 
of the patients had BMI ≥ 25, contradicting the inference of previous study by 
Jacobson BC et al(124) , who found that GERD symptoms exacerbation is more 
frequent in patients with BMI of ≥ 25. 
In addition, this study showed that out of 100 GERD patients, 69% had 
associated co-morbidities of which 48% had < 3 co-morbidities and 21% had ≥ 
3 co-morbidities. This finding supports the previous study by Moraes-Filho JPP 
et al(125), who postulated the strong association of co-morbidities with GERD 
and its worsening effect on GERD. 
Though heartburn, regurgitation and retrosternal chest pain are the classic 
presenting symptoms of GERD, in our study these symptoms were not seen in 
all the patients included in this study. Heartburn was absent in 26% of the 
patients and was present in 74% of the patients of which 11 patients had 
frequency of ≤ 2 episodes / week, 41 patients had frequency of  >  2 episodes / 
week and 22 patients had daily episodes of heartburn. Regurgitation was absent 
in 25% of the patients and was present in 75% of the patients of which 31 
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patients had frequency of ≤ 2 episodes / week, 25 patients had frequency of >  2 
episodes / week and 19 patients had daily episodes of regurgitation. Retrosternal 
chest pain was absent in 34% of the patients and was present in 66% of the 
patients of which 32 patients had frequency of ≤ 2 episodes / week, 9 patients 
had frequency of >  2 episodes / week and 25 patients had daily episodes of 
retrosternal chest pain. Furthermore, dysphagia and odynophagia have been 
described as third most common clinical symptom of GERD (126). In contrary, 
in our study 75% of patients didn’t have dysphagia and 82% of patients didn’t 
have odynophagia. Previous study by Kahrilas PJ et al (126) inferred that heart 
burn was present in nearly all GERD patients in their study and regurgitation 
was found in 80% of GERD patients, in contradiction to the results of our 
present study. Amongst 100 GERD patients in our study, 75 patients didn’t have 
positional variation of symptoms and rest 25 patients had positional variation of 
any of the GERD symptoms described above. 
In a previous study by Çela L et al(127), they inferred that the prevalence of 
GERD is significantly higher in smokers, alcoholics and individuals with 
increased frequency of consumption of meat, fried foods and spicy foods. In 
accordance with these findings, our study showed more number of patients 
(75%) are non-vegetarians and rest (25%) were vegetarians. Besides, we found 
the reverse trend in history of smoking, alcohol, intake of fried foods and spicy 
foods. In this study, amongst 100 GERD patients, 52 patients had history of 
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smoking and 48 patients didn’t have history of smoking, 44 patients had history 
of alcohol consumption and 56 patients didn’t have history of alcohol 
consumption, 51 patients had history of spicy foods consumption and 49 
patients didn’t have history of spicy foods consumption, 26 patients had history 
of history of intake of fried foods and 74 patients didn’t have history of intake 
of fried foods.  
Literature search revealed the refluxogenic properties of the following products: 
citrus fruits and juices, tomatoes, coffee / tea, aerated drinks and 
chocolate(128,129). Postulated mechanism by which these dietary products 
cause or aggravate GERD symptoms was by increased gastric juice secretion, 
delaying stomach evacuation and decreased LES pressure. In this present study 
we found that history of citrus fruits intake was absent in 87% of the patients 
and present in 13% of the patients, history of coffee / tea intake was absent in 
nearly half of the patients (44%) and present in 56% of the patients, history of 
intake of aerated drinks was absent in 93% of the patients and present in 7% of 
the patients. Our findings were in concordance with the previous study by Song 
JH et al (130), who confirmed the negative influence of these refluxogenic 
products on GERD.   
It was a common belief that eating habits such as heavy meals and eating 
directly before sleep might contribute to the occurrence of symptoms of GERD. 
Although previous studies by Iwakiri K et al(129) and Fujiwara et al(131) 
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postulated the negative influence of these eating habits on the aggravation or 
occurrence of GERD symptoms. In our study we inferred that history of heavy 
meal intake was absent in 67% of the patients and present in 33% of the 
patients, which postulates that no significant contribution of heavy meal intake 
towards occurrence of GERD symptoms which is in concordance with previous 
studies(129,131).  
In the previous study by Gross M et al (132) postulated that GERD had 
substantial effect on work productivity in study of 249 German patients with 
GERD, although patients were on routine clinical care and proton pump 
inhibitors therapy. In contrary to this finding we found that effect of work on 
GERD was absent in 91% of the patients and was present in 9% of the patients 
amongst 100 GERD patients included in this study. 
In another study by Jung H et al (133), inferred that complex relationship 
between GERD and sleep exists and further they suggested modest bidirectional 
association of GERD and sleep disturbance. In contrast to these findings, our 
study showed sleep disturbances were present in 32% of the patients and absent 
in 68% of the patients.  
In this present study, we found that Helicobacter pylori was present in 37% of 
the patients and was absent in 63% of the patients. Previous studies (134,135) 
by many authors proposed a strong argument regarding the protective role of 
Helicobacter pylori against GERD. Prevalence of Helicobacter pylori was 
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reported to be low about 5-10% in patients affected with GERD in comparison 
to the control groups by previous studies (134,135 ). Our findings were in 
contrast to these studies. 
Los Angeles classification system published in 1999 (136)
 
was the widely 
accepted for categorizing reflux esophagitis on UGI scopy. In this present study, 
57% patients had Grade A reflux esophagitis, 14% patients had Grade B reflux 
esophagitis, 11% of the patients had Grade C reflux esophagitis and 12% 
patients had Grade D reflux esophagitis.  
Complications of GERD includes erosive esophagitis with ulcers, Barrett’s 
esophagus and esophageal stricture. In previous study by Spechler SJ et al(137) 
, showed that esophageal adenocarcinoma is the most common complication of 
GERD and warranted serial endoscopic screening for development of Barrett’s 
esophagus. In another study by Chait MM et al (138)  postulated that 20% of the 
adults with GERD have serious complications. Supporting this finding, our 
study showed that 24% of the patients had complications (12% esophageal 
ulcer, 6% Barrett’s esophagus and 6% esophageal stricture) and rest 76% of the 
patients didn’t have complications. 
Furthermore in our study, we divided 100 GERD patients into two groups based 
on the presence of complications – GERD with complications and without 
complications. We analyzed the various demographic, symptomatology, 
lifestyle and endoscopic parameters between these two groups.  
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Of the demographic parameters, age of the patient showed significant 
association with the presence of complications (p= 0.000). Higher the age of the 
patient, higher the risk of complication. In addition, we derived cutoff of ≥ 58.5 
years (AUROC: 0.769) to depict the higher risk of complications in GERD 
patients with 83% sensitivity and 61% specificity. This finding was in 
contradiction to previous study by Thrift AP et al(139) , in which they has 
inferred that risk of GERD complications is higher in patients presenting at 
earlier in their life (<30 years). Apart from age of the patient, other 
demographic variables such as sex and BMI didn’t show statistical significance 
between these two groups. 
In the present study we found that heart burn, regurgitation, retrosternal chest 
pain showed significant association between GERD with complications and 
without complications groups. It can be postulated that daily episodes of heart 
burn (p=0.018) infers high risk of GERD complications. Similar trend can be 
inferred for regurgitation (p=0.023) and retrosternal chest pain (p=0.016). 
Although dysphagia and odynophagia showed p value of < 0.05, they didn’t 
exhibit strong association between these two groups due to lower likelihood 
ratio of 47.84 and 62.38 respectively. Rest of the clinical parameters such as 
number of co-morbidities and positional variation of symptoms didn’t show 
significant difference between these two groups. 
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Current study showed that neither of the lifestyle parameters such as smoking, 
alcohol, intake of meat, spicy foods, fried foods, citrus fruits, heavy meals, tea / 
coffee and aerated drinks had significant difference between GERD with 
complication and without complication. In addition, sleep disturbance and effect 
on work also didn’t show significant difference between these two groups. 
In our study, we inferred that presence of Helicobacter pylori in GERD patients 
signifies higher risk of complications (p=0.000). H.pylori was present in 83% of 
patients in in GERD with complications group and was absent in 78% of the 
patients in GERD without complications group. Although grades of reflux 
esophagitis showed p value of < 0.05, it didn’t exhibit strong association 
between these two groups due to lower likelihood ratio of 69.77. However, 
grades C & D were moderately higher in GERD with complications group. 
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SUMMARY 
GERD is one amongst the common gastro-esophageal junction pathologies 
encountered by gastroenterology specialists in day to day practice. Diverse 
studies on various population and lifestyle background had been reported in 
previous literature; however the data were few from our part of the country. 
Henceforth, warranting more studies representing the facts from our province of 
the country. Total of 100 patients who had been diagnosed as Gastro-esophageal 
reflux disease (GERD), based on upper gastrointestinal endoscopy were 
included in this study. Patients were interviewed for demographic details, 
lifestyle information, and symptomatology data. Mean age of GERD patients 
was 56.09 ± 15.93 years (Range: 20 – 82 years). From our study we inferred 
that GERD is more prevalent in males than females with male to female ratio of 
4:1. In addition we also postulated that GERD is more frequent in BMI < 25, 
more number of co-morbidities. Furthermore, we inferred the following 
findings from this study. Classical symptoms of GERD such as heartburn, 
regurgitation and retrosternal chest pain were not present in all the patients. 
Dysphagia and odynophagia were less frequent in GERD. GERD is more 
prevalent in non-vegetarians than vegetarians. No strong asscoiation of 
smoking, alcohol, spicy foods, fried foods, citrus fruits, heavy meals, tea/coffee, 
aerated drinks, sleep disturbance and effect on work in GERD. Helicobacter 
pylori was present in 37% of the patients, in contrary to previous studies which 
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showed inverse relation of H.pylori and GERD. Grade A reflux esophagitis is 
most common followed by B > D > C. Prevalence of GERD complications was 
24% in our population. Most common complication was erosive esophagitis 
followed by Barrett’s esophagus and esophageal stricture. Furthermore, we 
divided 100 GERD patients into two groups (GERD with complications and 
without complications) and analyzed the various demographic, 
symptomatology, lifestyle and endoscopic parameters between them. Age of the 
patient showed significant association with the presence of complications (p= 
0.000). Higher the age of the patient, higher the risk of complication. Cutoff of 
≥ 58.5 years (AUROC: 0.769) was derived from our study to depict the higher 
risk of complications in GERD patients with 83% sensitivity and 61% 
specificity. Daily episodes of heartburn, regurgitation and retrosternal chest pain 
implies higher risk of complications (p=0018, 0.023, 0.016 respectively). 
Presence of Helicobacter pylori in GERD patients signifies higher risk of 
complications (p=0.000).  
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CONCLUSION 
 Classical symptoms of GERD was not present in all the patients 
(Heartburn was present in 74% of patients, Regurgitation in 75% & 
Retrosternal chest pain in 66% of patients) 
 GERD is more common in non-vegetarians than vegetarians 
 Order of prevalence of grades of reflux esophagitis: A > B > D > C 
 Prevalence of GERD complications was 24% in our syudy with order of 
erosive esophagitis > Barrett’s esophagus and Esophageal stricture 
 Higher age of the patient infers higher risk of complications  
(Cut off : ≥ 58.5) 
 Daily episodes of heartburn, regurgitation and retrosternal chest pain 
implies higher risk of complications 
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LIMITATIONS OF THE STUDY 
 Single center experience 
 Terminally ill patients were not included in this study 
 Patients with esophageal mass were not included in this study, though 
adenocarcinoma of esophagus can occur secondary to GERD, but it has 
other multifactorial predispositions. 
 Future studies with large scale, multicenter and case control design 
focused on this context are warranted.  
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STUDY PROFORMA 
NAME - 
AGE- 
GENDER- 
HOSPITAL NO- 
CO-MORBIDITIES- 
 
SYMPTOMS  
FREQUENCY SCALE 
0 - NO SYMPTOMS 
1 - 1-2 EPISODES / WEEK 
2 - >2 EPISODES / WEEK 
3 - DAILY SYMPTOMS  
 
   SYMPTOMS 
         AND 
    DURATION 
      
          0 
     
       1 
       
       2 
       
       3 
 
   HEARTBURN 
 
 
    
   SYMPTOMS 
         AND 
    DURATION 
      
          0 
     
       1 
       
       2 
       
       3 
 REGURGITATION 
 
 
    
 
RETROSTERNAL        
CHEST PAIN 
 
 
    
 
DYSPHAGIA 
 
 
    
 
ODYNOPHAGIA 
 
 
    
 
HAEMETEMESIS 
 
 
    
 
OTHER SYMPTOMS IF ANY  
(ABDOMEN PAIN, BURPING, NAUSEA, VOMITING, COUGH, 
HOARSENESS OF VOICE OR ANY OTHER SYMPTOM) 
 
 DIET AND LIFESTYLE FACTORS ASSOCIATED WITH GERD 
 HEIGHT- 
 WEIGHT- 
 BMI- 
 SMOKING- 
 ALCOHOL- 
 
 VEGETARIAN OR NON VEGETARIAN- 
 SPICY FOOD- 
 FRIED FOOD- 
 CITRUS FRUITS- 
 TEA/COFFEE - 
{ IF YES-  FREQUENT ( > 3 COFFEE OR TEA / DAY) OR 
INFREQUENT ( < 3 COFFEE OR TEA / DAY)} 
 AERATED DRINKS -  
{IF YES-  FREQUENT ( > 5 DRINKS / WEEK) OR INFREQUENT ( < 5 
DRINKS / WEEK)} 
 DOES HEAVY MEALS AGGRAVATE THE SYMPTOMS - 
 DOES THE SYMPTOMS CAUSE SLEEP DISTURBNCE - 
 DOES THE SYMPTOMS AFFECT WORK - 
 POSITION VARIATION - DOES BENDING DOWN OR LYING DOWN 
IMMEDIATELY AFTER MEALS AGGRAVATE THE SYMPTOMS 
 
 
 
COMPLICATIONS IF ANY: 
 
 
 
 
ENDOSOPIC SEVERITY ACCORDING TO LA CLASSIFICATION : 
 
 
 
The Los Angeles Classification of Esophagitis: 
Grade A - One or more mucosal breaks no longer than 5mm that does    not extend 
between the tops of two mucosal folds 
Grade B - One or more mucosal breaks more than 5mm that does not extend 
between the tops of two mucosal folds 
Grade C - One or more mucosal breaks that is continuous between the tops of two 
or more mucosal folds, but which involve less than 75% of the mucosal 
circumference 
Grade D - One or more mucosal breaks which involves at least 75% of the mucosal 
circumference 
  
ABREVIATION 
GERD  -  Gastro Esophageal Reflux Disease 
LES   -  Lower Esophageal Sphincter 
UES   -  Upper Esophageal Sphincter 
CP   -  Cricopharyngeus 
TP   -  Thyropharyngeus 
IL-6   -  Interleukin 6 
TNF- α -  Tumor necrosis factor alpha  
PPI  -  Proton pump inhibitor 
OT  -  Omeprazole test  
OSA   - Obstructive sleep apnea 
OTC   -  Over-the -counter medication 
H2RAs  -  histamin-2 receptor antagonist 
NSAID  -  Non Steroidal Anti-inflammatory drugs 
BE   -  Barrett's esophagus 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
 
I Dr. Ganesh. S am carrying out a study on the topic: A STUDY ON CLINICAL PROFILE OF ENDOSCOPIC 
PROVEN GASTROESOPHAGEAL REFLUX DISEASE (GERD) as part of my / our research project being 
carried out under the aegis of the Department of General Medicine.   
 
My research guide is: Dr. Jayachandran. K MD 
                                    Dr. Mukundan. S MD DM 
 
The justification for this study is:  
Though GERD is more common in the western society, there have been recent increase in occurrence of 
GERD in India and Asian countries. There are not enough studies on GERD in the Indian population. 
Among these studies, there was inconsistency in the risk factors associated with GERD and prevalence of 
complications was less studied. This study will analyze the symptom profile of GERD, prevalence of 
complications and dietary & lifestyle factors associated with GERD. Upper gastrointestinal endoscopy 
has been regarded as gold standard for diagnosis of GERD. Hence endoscopic proven GERD patients will 
be included in the study to identify the specific symptoms and factors associated with GERD. This study 
will help in modifying the factors associated with GERD and improve the quality of life. By assessing the 
prevalence of symptoms and complications,  early prediction of GERD can be  possible.  
 
 
The objectives of this study are:  
 To analyze the symptom profile of GERD  
 To analyze the dietary and lifestyle factors associated with GERD.  
 To assess the prevalence of complications of GERD. 
 
 
Sample size: 100.  
 
Location: PSG HOSPITALS.  
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
 
Initial interview : 15 minutes.  
 
Data collected will be stored for a period of three years. We will / will not use the data as part 
of another study. 
Benefits from this study: This study helps in analyzing the symptom profile of GERD, factors 
associated with it and helps in modifying them there by helping improve the quality of life. 
through analyses symptoms and complications of GERD early prediction of the disease is 
possible. 
 
Risks involved by participating in this study: Nil 
 
How the results will be used: The results of this study will be submitted to DR MGR UNIVERSITY 
as a part of thesis program in post graduate course of General Medicine. 
 
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at 
anytime. You have the freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you so decide, will not 
result in any form of compromise or discrimination in the services offered nor would it attract 
any penalty. You will continue to have access to the regular services offered to a patient. You 
will NOT be paid any remuneration for the time you spend with us for this interview / study. 
The information provided by you will be kept in strict confidence. Under no circumstances shall 
we reveal the identity of the respondent or their families to anyone. The information that we 
collect shall be used for approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether directly related to you or 
to other participants of this study, developed during the course of this research which may 
relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has 
been explained to me by the investigator/s. Having understood the same, I hereby give my 
consent to them to interview me. I am affixing my signature / left thumb impression to indicate 
my consent and willingness to participate in this study (i.e., willingly abide by the project 
requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative: 
 
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
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S.No OP/IP no Age Sex Co-morbid Heart burn Regurg Retrosternal pain Dysphagia Odynophagia BMI Smoking Alcohol V/NV Spicy foods Fried food Citrus fruits Tea / Coffee Aerated drinks Heavy meals Sleep disturb Affect work Positional Var H.Pylori GERD Grades Complications
1 O01031911 59 M 0 3 3 3 3 0 18.2 0 0 1 1 0 0 2 0 0 0 0 0 1 C 1
2 O12007235 68 M 2 2 0 0 0 0 26.42 0 0 2 0 0 0 1 0 0 0 0 0 0 B 0
3 I16001189 63 M 2 0 1 0 1 0 22.59 1 1 2 0 0 0 1 0 1 0 0 0 1 A 0
4 O15035312 26 M 0 2 1 2 0 0 24.22 0 1 2 1 1 1 1 1 0 1 0 1 0 A 0
5 I16002776 54 F 3 2 2 0 0 0 36.26 0 0 2 1 1 1 1 0 1 1 1 1 1 A 0
6 I16003110 56 M 3 0 2 0 0 0 13.15 1 0 2 1 0 0 2 1 0 1 1 1 0 B 0
7 O16006682 27 M 0 1 1 0 0 0 20.7 1 1 2 1 1 0 1 0 1 1 1 1 0 B 0
8 I16020375 33 M 0 0 2 3 0 0 19.1 1 0 2 1 0 0 1 0 1 0 0 0 1 A 0
9 I16012144 36 M 0 1 1 0 0 0 21.58 0 0 2 0 0 0 0 0 0 0 0 0 0 A 0
10 I16009274 38 F 3 1 2 0 0 0 33.65 0 0 2 1 1 0 1 0 1 0 0 0 0 A 0
11 I16009052 45 M 0 2 2 0 0 0 24.22 1 1 2 1 0 0 1 0 0 0 0 0 1 A 0
12 I16009165 74 M 0 2 2 0 0 0 19.94 1 0 2 1 0 0 1 0 1 1 0 1 0 A 0
13 I16000403 72 F 1 2 2 1 0 0 25.3 0 0 2 1 1 0 2 0 0 1 0 1 0 A 0
14 I16000659 29 F 0 2 2 1 0 0 23 0 0 2 1 1 0 0 0 0 0 0 0 0 C 0
15 I16001237 30 M 0 2 1 1 0 0 26.3 1 1 2 1 1 0 1 1 1 1 0 1 0 A 0
16 I16001634 20 M 0 2 1 1 0 0 20.8 0 0 1 1 0 0 2 2 1 0 1 0 0 A 0
17 I16002525 42 M 1 2 1 2 0 0 25 1 1 2 1 1 0 1 2 0 1 1 0 0 A 0
18 I16003218 56 F 2 2 2 1 0 0 22.9 0 0 2 1 0 1 2 0 1 0 0 0 0 A 0
19 I16003288 50 F 1 3 3 3 3 3 20 0 0 1 1 0 0 1 0 0 0 0 1 1 D 3
20 I16020815 54 M 0 0 1 1 0 0 21 0 0 2 0 0 0 0 0 0 0 0 0 1 A 0
21 I17020529 38 M 0 0 1 1 0 0 22.8 0 1 2 0 0 0 0 0 0 0 0 0 0 A 0
22 I16019979 64 M 2 0 1 1 0 0 17.6 1 0 2 0 0 0 0 0 0 0 0 0 0 A 0
23 I16024277 80 F 0 3 3 3 3 3 18.7 0 0 1 1 0 0 1 0 1 1 0 1 1 C 1
24 I16024511 58 M 0 2 1 1 0 0 18.3 0 0 2 1 0 0 0 0 0 0 0 0 1 B 0
25 I16024420 56 M 0 2 2 1 0 0 16.4 0 0 2 1 0 1 0 0 1 1 0 1 0 A 0
26 O14087103 47 M 0 1 1 1 0 0 21 1 1 2 1 0 1 1 0 1 1 0 0 0 A 0
27 I16024391 20 M 1 0 2 1 0 0 22.6 0 0 1 0 0 0 0 0 0 0 0 0 1 A 0
28 O10024084 42 M 0 1 1 1 0 0 27.7 0 0 2 0 0 0 0 0 1 1 0 1 1 A 0
29 I16025733 71 M 0 1 1 1 0 0 19.7 1 1 2 1 0 1 0 0 1 0 0 0 0 A 0
30 I16025663 82 M 4 2 3 0 3 1 32 0 0 2 1 0 0 1 0 0 0 0 1 1 C 0
31 I16038935 76 F 2 2 2 3 0 0 17.8 0 0 1 1 1 0 0 0 1 1 0 0 1 A 0
32 I16039511 65 F 0 0 1 0 3 0 14.9 0 0 2 0 0 0 0 0 0 0 0 0 0 A 0
33 I16038689 60 M 4 2 1 2 3 0 22.1 1 1 2 0 0 0 0 0 0 0 0 0 0 C 0
34 I16039715 53 M 2 0 1 1 1 0 28.4 0 1 1 0 0 0 0 0 0 0 0 0 0 B 0
35 I16039331 43 M 1 0 1 1 0 0 23.2 1 1 2 1 1 0 0 0 1 1 0 1 0 A 0
36 I16039359 50 M 5 2 2 1 0 0 15.2 1 0 2 1 1 0 1 0 1 1 0 0 0 A 0
37 I16040004 64 M 1 3 2 3 3 3 22.5 0 0 1 1 1 0 0 0 1 1 0 0 1 D 3
38 I16039439 42 M 3 0 1 1 0 0 14.8 1 1 1 0 0 0 0 0 0 0 0 0 0 A 0
39 I16040017 58 M 1 2 1 1 0 0 16 0 0 2 1 0 0 1 0 0 1 0 0 0 A 0
40 I16025398 65 M 0 2 1 1 0 0 18.3 0 0 2 1 0 0 0 0 0 0 0 0 1 B 0
41 I16004846 75 M 4 3 3 3 3 3 18.1 1 1 2 0 0 0 0 0 0 0 0 0 1 B 1
42 I16005612 29 M 0 2 1 1 0 0 26.6 1 0 1 1 0 1 0 0 0 0 0 1 0 A 0
43 I16006481 59 F 2 0 1 0 0 0 22.9 0 0 1 0 0 0 0 0 0 0 0 0 0 A 0
44 I16006824 52 M 0 0 1 0 0 0 25.3 1 1 1 0 0 0 0 0 0 0 0 0 0 A 0
45 I16008675 82 F 1 3 3 3 0 0 22.6 0 0 1 0 0 0 0 0 0 0 0 0 1 D 2
46 I16017399 59 F 2 0 1 0 0 0 21.9 0 0 1 0 0 0 0 0 0 0 0 0 0 A 0
47 I16010657 79 M 2 3 3 3 3 2 21.5 1 0 1 0 0 0 0 0 0 0 0 0 0 C 3
48 I16011661 66 F 1 3 3 3 3 3 25.4 0 0 2 0 0 0 0 0 0 0 0 0 1 C 1
49 O96003284 23 M 0 2 2 0 0 0 24.5 0 1 2 1 1 0 0 2 0 0 0 0 0 C 0
50 I16012733 42 F 1 3 3 3 0 0 24 0 0 1 0 0 0 0 0 0 0 0 0 1 D 2
51 I16012759 61 M 3 2 1 0 0 0 24.2 1 1 2 1 1 0 1 0 0 0 0 0 0 A 0
52 I16012847 78 M 3 2 1 0 0 0 23.3 1 1 2 1 0 0 2 0 1 0 0 0 0 A 0
53 I16013620 42 M 2 0 0 0 0 0 24 0 1 1 0 0 0 0 0 0 0 0 0 0 A 0
54 I16018735 51 M 0 2 0 3 0 0 25.2 1 1 2 1 1 0 1 0 1 0 0 0 1 B 0
55 I16018887 68 F 2 3 3 2 0 3 30.2 0 0 1 0 0 0 0 0 0 0 0 0 0 C 1
56 I16018929 73 F 1 3 3 3 2 3 21.5 0 0 2 1 0 0 1 0 0 0 0 0 1 D 1
57 I16022983 71 M 1 0 0 0 0 0 20.8 1 1 2 0 0 0 0 0 0 0 0 0 0 A 0
58 I16023299 74 M 3 3 3 3 2 3 22.6 1 1 2 0 0 0 0 0 0 0 0 0 1 C 3
59 I16023360 38 M 0 0 0 0 0 0 27.7 0 1 2 0 0 0 0 0 0 0 0 0 0 A 0
60 I16024020 56 M 3 2 0 0 0 0 23.3 1 1 1 0 0 0 1 0 1 0 0 0 0 B 0
61 I16024158 60 M 2 2 3 3 3 2 21.8 1 1 2 0 0 0 2 0 1 1 0 1 1 D 1
62 I16024511 59 M 2 0 0 1 0 0 23.7 1 0 1 0 0 0 0 0 0 0 0 0 0 B 0
63 I16026719 61 F 1 0 0 1 0 0 25.4 0 0 1 0 0 0 0 0 0 0 0 0 0 A 0
64 I16027041 53 M 2 2 2 1 0 0 26.1 1 0 2 1 0 0 1 0 0 1 1 0 1 A 0
65 I16027262 63 M 2 2 2 3 3 3 24.9 1 0 2 0 1 0 1 0 0 0 0 0 1 D 3
66 I16027603 49 F 2 2 0 3 0 0 24.4 0 0 2 1 0 0 1 0 1 0 0 0 0 B 0
67 I16028987 41 M 1 3 3 2 0 0 22.8 1 1 2 0 1 0 1 0 0 1 0 1 1 C 2
68 I16029604 67 M 2 2 0 1 0 0 19.8 1 0 2 1 0 0 1 0 0 1 0 1 0 B 0
69 I16031637 35 M 1 0 0 1 0 0 25.4 0 0 1 0 0 0 0 0 0 0 0 0 0 A 0
70 I16032818 75 M 1 2 3 3 3 3 24.2 1 1 2 1 1 0 2 0 0 1 1 0 1 C 1
71 I16034991 54 F 1 2 0 1 0 0 21.9 0 0 2 1 1 0 1 0 0 0 0 0 0 A 0
72 I16038963 60 M 3 3 3 3 2 3 21.5 0 1 2 0 0 0 0 0 0 0 0 0 1 B 1
73 I16038970 65 M 1 2 2 1 0 0 25.5 1 1 1 1 1 0 2 0 0 0 1 0 0 B 0
74 I16040124 67 M 2 0 2 1 0 0 22.9 1 1 2 0 0 0 0 0 0 0 0 0 1 A 0
75 I17002627 82 M 5 3 3 2 3 3 19.8 1 1 2 0 0 0 0 0 0 0 0 0 0 C 1
76 O11025732 49 M 1 2 0 0 0 0 26.3 1 1 2 1 0 0 1 0 1 1 0 1 0 A 0
77 I17008205 59 M 4 2 0 2 0 0 28.4 1 1 2 1 0 1 2 0 1 1 0 0 0 A 0
78 I17008241 38 M 1 0 0 0 0 0 22.3 1 0 2 0 0 0 0 0 0 0 0 0 0 C 0
79 I17009865 66 F 1 3 2 3 3 2 21.1 0 0 1 1 1 1 2 0 0 1 0 1 1 D 1
80 I17010039 74 M 3 3 3 3 3 3 22.6 1 0 2 1 0 0 0 0 0 0 0 0 0 D 1
81 I17010144 70 F 3 2 0 1 1 0 20.7 0 0 2 1 1 1 1 0 0 1 0 1 1 A 0
82 I17010284 73 M 3 2 2 3 0 0 32 0 0 2 1 0 0 1 0 1 0 0 0 1 C 2
83 I17010356 72 M 1 2 0 1 0 0 22.6 1 1 2 1 0 0 2 0 0 1 0 0 0 A 0
84 O17019900 70 M 5 0 0 1 0 0 22.5 1 1 2 0 0 0 0 0 0 0 0 0 0 A 0
85 I17010866 29 M 0 1 1 0 0 0 23.7 1 1 2 1 0 0 1 0 1 0 0 1 0 A 0
86 I17012100 67 F 1 1 1 0 0 0 29.3 0 0 2 1 0 0 1 0 1 0 0 0 0 A 0
87 I17013086 57 F 1 1 1 0 0 0 31.1 0 0 2 1 0 1 2 0 0 1 0 0 0 A 0
88 I17013687 60 F 2 2 2 0 0 0 26.7 0 0 1 1 0 0 1 0 0 0 0 0 0 A 0
89 I17015783 64 M 0 3 3 2 0 0 21.5 1 1 2 1 1 0 1 0 1 0 0 1 1 D 2
90 O17014189 44 M 0 1 0 0 1 0 26.7 1 1 2 0 0 0 1 0 0 0 0 1 1 A 0
91 O17038097 54 M 2 1 0 0 0 0 22.9 1 1 2 1 0 0 2 0 1 0 0 0 0 A 0
92 I17022113 82 M 2 3 2 3 0 0 23.1 1 1 2 1 1 0 1 0 1 1 0 0 1 C 2
93 I17022524 40 M 1 0 0 3 1 0 27.7 0 0 2 1 0 0 2 0 0 1 0 1 0 A 0
94 I17023248 56 M 0 3 2 3 3 3 29 1 0 2 1 0 0 1 0 1 0 0 0 1 D 3
95 I17023827 57 F 1 2 0 0 0 0 24.3 0 0 2 0 1 1 2 0 0 1 0 1 0 A 0
96 I17024725 81 M 5 0 0 0 0 0 28.03 1 1 2 0 0 0 0 0 0 0 0 0 0 A 0
97 O17045878 33 M 0 0 0 2 0 0 23.2 1 1 2 0 0 0 0 0 0 0 0 0 1 A 0
98 O17038337 80 M 3 2 2 0 0 0 22.6 1 1 2 1 0 1 2 0 0 1 0 0 0 C 0
99 I17026631 66 M 2 3 0 0 0 0 23.9 1 0 2 1 0 0 1 0 1 0 0 0 0 D 0
100 I17029114 33 M 0 3 1 0 0 0 27.7 1 1 2 1 1 0 1 1 0 0 1 0 0 A 0
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